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 Enzymes are efficient biological catalysts that enormously accelerate the rates of 
chemical reactions by many orders of magnitude compared to the uncatalyzed reaction. 
The remarkable catalytic rate enhancement derives from the enzymes three dimensional 
structure, folding along with the active site geometry and packing. An enzyme active site 
has selective affinity for the substrates and stabilizes high-energy chemical species and 
unstable intermediates during the catalysis. To enhance the enzyme’s catalytic ability, 
many enzymes have also evolved coenzymes (or) cofactors for catalysis. These cofactors 
often provide chemical functionality and reactivity that are not accessible to the twenty 
canonical amino acids. Thus, cofactors mediate diverse and unique chemical reactions 
that are catalyzed by enzymes. Isopentenyl diphosphate:dimethylallyl diphosphate 
isomerase were identified in two isoforms (IDI-1 and IDI-2) that catalyze the 
IPP/DMAPP isomerization. The work described in this dissertation focuses on attempts 
towards understanding the role of flavin cofactor in the chemical mechanism of type II 
isopentenyl diphosphate:dimethylallyl diphosphate (IDI-2) isomerase as well as 
mechanistic studies of IDI-1 and IDI-2. In the first section of this dissertation, studies will 
focus on the engineered enzyme variant of type II isopentenyl diphosphate:dimethylallyl 
diphosphate isomerase (IDI-2) from Streptococcus pneumoniae, a crucial enzyme in the 
isoprenoid biosynthetic pathway that utilizes a flavin mononucleotide (FMN) cofactor for 
catalysis. In most enzymes, flavin cofactors mediate redox electron transfer reactions.
	   
iv 
However, the IDI-2 catalyzed reaction involves no net redox change, raising questions on 
the role of the flavin in IDI-2 chemical mechanism. The chemical mechanism of IDI-2 
will be studied with a combination of spectroscopic studies and biochemical techniques. 
Others and our studies suggest that the flavin cofactor of IDI-2 may employ an unusual 
and novel mode of flavin-dependent catalysis involving acid/base chemistry. In the 
second section, attention will be focused on the site-selective synthesis of 15N- and 13C-
enriched flavin isotopologues to understand the acid/base functionality of flavin in the 
chemical mechanism of IDI-2. Finally, mechanistic studies of IDI-1 and IDI-2 in D2O 
will address that the IPP/DMAPP isomerization is very likely proceeding through a step-
wise mechanism via a tertiary (3o) carbocationic intermediate. Taken together, kinetic, 
mechanistic, and spectroscopic studies on IDI-2 demonstrate that it catalyzes the reaction 
utilizing a flavin coenzyme in an atypical manner where the coenzyme performs 
acid/base chemistry instead of redox chemistry in which the later is the typical function 
of flavin cofactor.  
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Background and Significance 
Isoprenoids (also called terpenoids) are natural products derived from two 
fundamental and ubiquitous five-carbon precursors, isopentenyl diphosphate (IPP) and 
dimethylallyl diphosphate (DMAPP), which are found in all the three domains of life 
(Eukaryota, Bacteria, and Archaea) (Figure 1.1). There are more than 68,000 isoprenoid 
natural products discovered to date.1 Isoprenoids serve various biological roles such as 
electron-transport carriers, vitamins, stabilization of membranes, photosynthetic pigments 
in plants, and antibiotics to name a few.2 Isoprenoid compounds have important 
biological roles in both primary and secondary metabolic pathways (nonessential but 
important for survival of the organism). 
Few representative examples of isoprenoids shown in Figure 1.2 include the 
monoterpene menthol,3 the flavor constituent caryophyllene,4 the antimalarial drugs 
artemisinin, and quinine,5,6 the plant hormone abscisic acid,7 the steroid molecule 
cholesterol,6 the electron transport component in the mitochondrial respiratory chain 
coenzyme Q,8 the anti-cancer agent taxol,6 the vitamin A precursor β-carotene,9 the 
earthy-oderant produced by Streptomyces soil bacteria 2-methylisoborneol,10 the antiviral 







Carbon skeletons of isoprenoid natural products are constructed from IPP and 
DMAPP by chain-elongation enzymes12-14 in a series of reactions that give geranyl 
diphosphate (GPP, monoterpene), farnesyl diphosphate (FPP, sesquiterpene), 
geranylgeranyl diphosphate (GGPP, diterpene), sesterpenes (C25), and longer chain linear 
diphosphates with branch points from FPP to produce squalene (C30) and from GGPP to 
give phytoene (C40) etc. (Figure 1.3). These five-carbon units and chain-elongated 
products can undergo a wide variety of reactions such as branching, condensation, and 
cyclization reactions, and so forth, to generate the structurally diverse array of natural 
products found in nature.15-17 
 
 
Biosynthesis of IPP and DMAPP 
There are two known biosynthetic pathways for the synthesis of IPP and DMAPP: 
the mevalonate pathway (MVA) and the nonmevalonate or methylerythritol phosphate 
(MEP) pathway (Scheme 1.1 and 1.2). The MVA pathway, discovered in the 1960s,2,18-22 
is utilized by eukaryotes, archaea, and some eubacteria is the established pathway. The 
MEP pathway, which was discovered in 1996,23-25 found in plant chloroplasts, algae, and 
most bacteria. Organisms utilizing the MEP pathway include several pathogens such as 
Mycobacterium tuberculosis, Plasmodium falciparum, and Listeria monocytogenes. The 
MEP pathway is orthogonal to the corresponding the MVA pathway in humans and is an 




The MVA pathway (Scheme 1.1) starts with the condensation of two molecules of 
acetyl-CoA catalyzed by acetyl-CoA acyltransferase to form acetoacetyl-CoA, which is 
then condensed with another molecule of acetyl-CoA by HMG-CoA synthase to form 3-
hydroxy-3-methylglutaryl-CoA (HMG-CoA). In the next step, HMG-CoA reductase 
catalyzes the reduction of HMG-CoA with two molecules of NADPH to form mevalonate 
(MVA).29 HMG-CoA reductase is the target for the highly effective statin class of 
cholesterol-lowering drugs.30 The later steps in the pathway include two successive ATP-
dependent phosphorylations of mevalonate and mevalonate-5-phosphate by mevalonate 
kinase (MVK) and phosphomevalonate kinase (PMK) to form mevalonate-5-
diphosphate,31 which is then converted into IPP by an ATP-dependent decarboxylation by 
mevalonate diphosphate decarboxylase (MPD).32,33 Interestingly, in archaea there is a 
hypothetical phosphomevalonate decarboxylase (PMD) that uses mevalonate-5-
diphosphate to produce isopentenyl phosphate (IP). IP undergoes phosphorylation by 
isopentenyl phosphate kinase (IPK) to generate IPP.34 IPK is a well-characterized 
enzyme. In the final step of the MVA pathway, IPP and DMAPP are interconverted by 
the action of isopentenyl diphosphate:dimethylallyl diphosphate isomerase (IDI).35  
 
 
Non-MVA or MEP Pathway 
The MEP pathway for biosynthesis of IPP and DMAPP (Scheme 1.2)36-38 starts 
with the condensation of pyruvate and glyceraldehyde-3-phosphate (G3P) to form 1-
deoxy-D-xylulose-5-phosphate (DXP), which is also an intermediate in the biosynthesis 
of thiamin (vitamin B1) and pyridoxine (vitamin B6).39 In the first committed step in the 
	   
4 
MEP pathway, DXP-reductoisomerase (DXR) catalyzes the conversion of DXP to 2-C- 
methyl-D-erythritol-4-phosphate (MEP), followed by cytidylylation, phosphorylation, 
and cyclization, catalyzed by the enzymes IspD, IspE, and IspF to generate the cyclic 2,4-
diphosphate (MECDP).40-42  
The two final steps in the MEP pathway are catalyzed by the [4Fe-4S] cluster 
containing enzymes IspG and IspH, which catalyze two consecutive 2e- reductions of 
MECDP to give methyl hydroxylbutyl diphosphate, followed by reduction to an 85:15 
ratio of IPP and DMAPP.43,44 Both IspG and IspH are potential antimalarial, anti-
tubercular, and antiherbicidal drug targets.  
 
 
Isopentenyl Diphosphate:Dimethylallyl Diphosphate Isomerase 
(IDI) 
Isopentenyl diphosphate:dimethylallyl diphosphate isomerase (IDI), which 
interconverts IPP and DMAPP (Scheme 1.1), is an essential enzyme in organisms 
utilizing the MVA pathway. In contrast, organisms utilizing the MEP pathway (Scheme 
1.2) do not require IDI since both IPP and DMAPP are generated as a mixture.45 In this 
case, IDI might exist in these organisms to balance the cellular pools of IPP and DMAPP. 
Two nonhomologous isoforms of IDI have been identified, type I IDI (IDI-1) and type II 
IDI (IDI-2). The amino acid sequences of IDI-1 and IDI-2 do not have significant levels 
of similarity although the enzymes catalyze the same transformation. IDI-1 requires Zn2+ 
and Mg2+ for catalysis and utilizes acid/base chemistry to facilitate the 1,3-proton 
addition/elimination reaction. IDI-2 requires a flavin mononucleotide (FMN) coenzyme 





 IDI-1 was discovered in 1959 by Lynen and coworkers during their studies of 
squalene biosynthesis in baker’s yeast.35,46 They demonstrated that IDI-1 catalyzed the  
reversible interconversion of IPP and DMAPP and subsequently purified the enzyme 
from yeast, pig liver, rat liver, kidney, and brain tissues.47,48  	  	   IDI-1 requires two divalent metal ions for catalysis. Mg2+ binds the diphosphate 
moiety in IPP and Zn2+ orients the active site residues in a catalytically competent 
conformation by coordinating to three histidines and two glutamates in an octahedral 
complex.49-51 The crystal structures of E. coli and Human IDI-1 with 2-
(dimethylamino)ethyl pyrophosphate (NIPP) and ethanol amine diphosphate (EAPP) 
substrate analogs show the structure of the active site, where highly conserved E116, C67 
(E. coli), and E148 and C86 (Human) (Figure 1.4) residues directly play a role in the 
catalysis.52,53 Studies with electrophilic IPP and DMAPP analogues, mechanism-based 
inhibitors (NIPP, (Z)-CF3-DMAPP, eIPP, OPP, etc.) and site-directed mutants indicated 
that C67, E116, and Y104 (E. coli numbering) are important catalytic residues for 
acid/base catalysis with Y104 performing a structural role in the transfer of a proton from 
E116 to the double bond in IPP.54-60 The C67A mutant of E. coli IDI-1 formed an 
irreversible covalent adduct between eIPP and an active site glutamate E116,61 whereas 
in wild-type (wt) IDI-1, C67 forms a covalent adduct with eIPP (Figure 1.5).52 
Additionally, the W136 residue near IPP could stabilize formation of the tertiary IPP 
carbocation or carbocationic transition state through cation-π interactions. These results 
are consistent with a mechanism where the electrophilic protonated epoxide group in 
eIPP is opened by nucleophilic attack by E116 or C67. The C67A mutant did not turn 
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over IPP; whereas, the C67S mutant catalyzes the isomerization ~104-fold more slowly 
that wt IDI-1.55 Thus, E116 protonates C4 of IPP and C67 abstracts the proton on C2 to 
generate DMAPP. In addition, Cys and Glu are ideally positioned on the opposite faces 
of the plane of IPP to facilitate the antarafacial stereochemistry observed for protonation-
deprotonation.52,56 Additional support for the carbocationic mechanism was obtained 
from kinetic studies with (Z)-CF3-DMAPP, which has ~106 fold reduced enzymatic and is 
similar to the ~107
 
decrease of the rate of solvolysis of the corresponding 
methanesulfonate (Figure 1.6), which presumably proceeds via a carbocation 
intermediate by an SN1 mechanism.62,63 
Support for a mechanism involving an IPP 3o carbocation intermediate (Scheme 
1.3) was also gained by designing a transition state mimic NIPP that mimics the 3o 
carbocation. It was found that NIPP is a tight-binding inhibitor of IDI-1 with a 10-100 
pM binding affinity which is 4 to 5 orders of magnitude tighter than IPP or DMAPP 
binding.58,59 Upon denaturation of IDI-1, NIPP was released into solution, indicating that 
the inhibition is of a noncovalent in nature. Studies with electrophilic analogs of IPP 
(Figure 1.7) including fluoro and epoxy substituents led to the formation of irreversible 
covalent adducts with the enzyme and further supports the 3o carbocationic intermediate 
or a transition state with substantial carbocationic character. The representative IPP 
analogs used to probe the mechanism of IDI-1 are shown in Figure 1.7. 
Furthermore, previous studies also defined the stereochemical outcome of the 
IDI-1 catalyzed IPP isomerization. Studies by Cornforth and coworkers with 4-3H-
labeled mevalonate showed that the pro-R C2 proton in IPP is stereospecifically removed 
during isomerization and subsequent studies with 2-3H-mevalonate indicated that the 
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proton is added on to the re face of the IPP double bond generating a carbocation or 
carbocation-like transition state. Utilizing 2-14C-mevalonate they also demonstrated that 
IPP isomerization to DMAPP in which the newly formed methyl group in DMAPP is in 
E-configuration.48,49,64 Taken together, the IDI-1 catalyzed IPP, DMAPP interconversion 
was suggested to be highly stereospecific involving 1,3-proton addition/elimination.   
Poulter and coworkers performed another crucial study with S. cerevisiae IDI-1 and 
demonstrated that all the hydrogens in IPP and DMAPP, except for those at C1, were 
ultimately exchanged for deuterium when the substrates were incubated with IDI-1 in 
D2O (Scheme 1.4).65 This result suggests that the IDI-1 active site does not rigidly control 
the stereochemistry of the requisite proton transfers during turnover. Likely, explanations 
for this lack of stereo- and regioselectivity are the presence of alternative acid/base 
groups in the enzyme active site and/or the presence of different IPP/DMAPP binding 
modes.  
Based on all the studies with IPP analogs, crystal structures, site-directed 
mutagenesis, kinetic studies, and identifications of the adducts by both chemical and X-
ray structural methods, the generally accepted mechanism of IPP isomerization by IDI-1 
is depicted in Scheme 1.5. Although, many groundbreaking mechanistic studies using IPP 
substrate analogs support the 1,3-proton addition/elimination mechanism of IPP that 
proceeds via a tertiary (3o) carbocation or carbocation-like transition state, there is no 
direct evidence as to the exact nature of the intermediate or transition state. While 
literature precedent for 3o carbocationic intermediate were observed for downstream 
isoprenoid biosynthetic enzymes such as the prenyltransferases and terpene cyclases 
whose substrates are allylic precursors, these are not directly relevant to 3o carbocation 
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formed from IDI isomerization.66,67 Previously, Richard and coworkers provided some 
clues into the nature of the IDI-1 catalyzed 1,3-proton addition/elimination of IPP with 
their model studies for the stepwise, acid-catalyzed isomerization of 4-(4-
methoxyphenyl)-2-methyl-1-butene in a mixture of trifluoroethanol:H2O 20:80 (v/v) at 
pH 7.0.68,69 Based on the comparisons of rate constants of individual steps of the 
nonenzymatic reaction of 4-(4-methoxyphenyl)-2-methyl-1-butene (Scheme 1.6A) and 
the IDI-1 catalyzed reaction of IPP (Scheme 1.6B), a rate enhancement of the enzyme 
catalyzed reaction kcat/knon was ~ 1011. The observed rate enhancement is likely derived 
from the electrostatic and cation-π stabilization of the carbocationic 
intermediate/transition state by the IDI-1 active site. Based on the model studies and 
comparisons of the free energy profiles of the deprotonation of a carbocation versus 
protonation of an enolate, the authors emphasize that the kinetic barrier for the 
carbocation deprotonation is significantly smaller compared to protonation of the enolate 
intermediate. From these studies the authors favored a concerted mechanism of IDI-1 
catalyzed IPP isomerization that does not go through a carbocationic intermediate. This 
result is in contrast to the step-wise mechanisms for enzymes that catalyze reversible α-
deprotonation of carbonyl compounds via enolate intermediates, where there is a large 
intrinsic advantage to general base catalysis. For these reasons, the authors of this study 
favored a concerted protonation/deprotonation mechanism for IDI-1. However, to date, 
no conclusive experimental evidence to distinguish among these mechanistic possibilities 
for IDI-1 has been reported.  
In 2012, Richard and coworkers reported a study of the hydrogen exchange in IPP 
catalyzed by IDI-1 in D2O. They identified that IDI-1 catalyzed process produces 66% of 
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the product DMAPP that has one deuterium on the E-methyl group and 34% of the 
substrate IPP that has also one deuterium at C2 position (Scheme 1.7).70 Based on the 
time-course of the enzyme assays, they identified that the product DMAPP formation was 
accompanied with the concomitant formation of d-IPP (1) along with the disappearance 
of IPP. These observations helped to propose the rates of individual steps in IPP/DMAPP 
isomerization in which d-DMAPP isomerization to d-IPP (k1-1) is faster than the product 
(d-DMAPP) release (kdis). Since the product release is the slow step they further added 




Archaea and eubacteria were known to employ the MVA pathway for the 
biosynthesis of isoprenoids but apparent lack of orthologs for mammalian IPP isomerase 
in these organisms fueled the search for IDI.71 In 2001, Seto and coworkers discovered 
the gene orfD contained an open reading frame (ORF) encoding a protein of unknown 
function when they cloned a gene cluster containing MVA pathway enzymes from 
Streptomyces sp. strain. They discovered that orfD encoded a flavin-dependent enzyme 
that catalyzes the reversible isomerization of IPP and DMAPP.72 This protein, named 
IDI-2, has no sequence similarity with IDI-1. Interestingly, IDI-2 was found in gram-
positive bacteria that are known to use the MVA pathway such as Staphylococcus aureus, 
Streptococcus pneumoniae, and Enterococcus faecalis but are absent in humans. This 
represents an attractive strategy from the drug design standpoint. IDI-2 prefers flavin 
mononucleotide (FMN) as a cofactor, with flavin adenine dinucleotide (FAD) 
approximately half as effective. No activity was detected with riboflavin.73 The enzyme 
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also required a reducing agent (for example NADPH) and a divalent metal ion (Mg2+, 
Mn2+ or Ca2+) for activity. The authors further demonstrated that the idi2 complemented 
an idi1 deletion in E. coli, suggesting that the biological function of IDI-2 is 
isomerization of IPP to DMAPP. 
 
 
Flavins and Flavocoenzymes in Enzyme Catalysis 
Flavin coenzymes commonly undergo two electron redox changes in various 
enzymatic transformations. The structures of oxidized, semiquinone, and reduced flavins 
are shown in Figure 1.8. Studies indicated that the pro S hydrogen of NADPH is 
transferred to FMN during reduction of the IDI-2FMNox complex, suggesting that 
NADPH is likely to be the physiological reductant.74 Subsequent studies showed that 
upon reduction of IDI-2FMNox to IDI-2:FMNred, the enzyme retained activity for 
multiple turnovers.74,75 Thus, there is no net redox change in FMNred after completion of 
each catalytic cycle, as expected for a reaction where there is no net change in the redox 
state of the substrates. UV-vis studies of enzyme bound FMNox (EFMNox) has 
characteristic peaks at ~376 nm and ~ 454 nm. (EFMNox) undergoes reduction with 
NADPH to give EFMNred that has a characteristic peak at ~ 352 nm indicating anionic 
FMNred. When IPP/DMAPP binds the anionic FMNred complex (EFMNred), there is a 
new peak at ~426 nm and a shoulder at ~320 nm indicating protonation of anionic 
EFMNred  (Scheme 1.8).76  
Liu and coworkers established that the pro-R hydrogen at C2 was removed from 
IPP during isomerization in incubations with (S)- and (R)-[2-2H]IPP (Figure 1.9A).77 
Similarly, Barkley et. al. found that the pro-R C2 hydrogen and C4 hydrogens of IPP and 
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E-methyl protons in DMAPP are replaced by deuterium when incubations were 
conducted in D2O with no detectable exchange of the pro-S C2 hydrogen in IPP or the 
hydrogens in the Z-methyl group in DMAPP (Figure 1.9B).78 These observations indicate  
that the proton transfer steps catalyzed by IDI-2 catalyzed are more stereoselective than 
those for IDI-1. Steinbacher and coworkers reported the first X-ray crystal structure of 
IDI-2 for the protein from Bacillus subtilis (bsIDI-2) at 2.8 Å resolution.79 The enzyme 
adopts a classical TIM-barrel fold, which is structurally distinct from the α/β fold adopted 
by IDI-1.56 Crystal structures were obtained both in the presence and absence of FMN 
because FMN was lost during protein purification and the protein was reconstituted with 
FMN by soaking with the protein. Shortly afterward, Hemmi and coworkers obtained an 
X-ray structure of Sulfolobus shibatae IDI-2 (ssIDI-2) at 2.2 Å (Figure 1.10A)80 (Figure 
1.10B). The ssIDI-2 structure contained FMNred, IPP and Mg2+ in the active site and 
provided important information about which conserved active-site amino acids are in 
contact with FMNH2 and IPP (Figure 1.10C).  
In the ssIDI-2 active site, IPP is located in a “box” with walls formed by His155, 
Trp225, Lys193, and Gln160 (S. shibatae numbering), and a floor formed by the 
isoalloxazine ring in FMN. Distances between C2 and C4 of IPP (where IPP/DMAPP 
undergoes the 1,3-proton addition/elimination) to the N1 and N5 of flavin is shown on 
Figure 1.10D. The next question was the mechanism of IPP/DMAPP isomerization. IPP 
and DMAPP can undergo isomerization either by hydrogen atom addition-abstraction or 
protonation-deprotonation mechanism as depicted in Figure 1.11. When IDI-2FMNIPP 
complex was reduced irrespective of the reducing agent, a flavin semiquinone radical was 
detected by EPR.76 However, flavin semiquinone radical species was not detected when 
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the IPP was added to the prereduced complex IDI-2.FMNH-. Attempts to detect the 
substrate IPP, flavin semiquinone radical pair were unsuccessful although the redox 
potentials are different for free flavin and the flavin bound to the enzyme.74,81 Although 
observed by UV-vis, the detection of flavin semiquinone radical by stopped-flow failed.82 
Furthermore, studies with radical clock analogs of IPP, cyclopropyl (cIPP), and epoxy 
IPP (eIPP) analogs, which should operate through radical mechanism via ring opening 
and a “radical clock rearrangement”83,84 indicated that cIPP isomerized to the cDMAPP 
product (Figure 1.12A) and eIPP formed a covalent adduct with flavin which could 
happen only by protonation of epoxide followed by ring opening (Figure 1.12B).85 These 
studies support the protonation-deprotonation mechanism rather than radical mechanism 
of IPP/DMAPP isomerization and provide insights about the close contacts between 
flavin and the substrate in the active site. 
Additional support for the protonation-deprotonation mechanism of IDI-2 came 
from studies with substrate analogs eIPP, vIPP, and fmIPP, which were potent 
electrophilic mechanism-based inhibitors of IDI-1 upon activation by protonation.86-88 
Incubation of these substrates led to the formation of flavin inhibitor adducts rather than 
the corresponding isomerized products. UV-vis spectral features first indicated the 
inhibitors attached to N5 of flavin but more thorough investigation showed that inhibitor 
analogs modified C4a of flavin through alkylation.79 FmIPP and vIPP are also alternate 
substrates in addition to functioning as inhibitors. Z-fmDMAPP, Z-dfmDMAPP analogs 
were found to be alternate substrates of the enzyme. Although NIPP strongly inhibits IDI-
1 at a much greater affinity, it weakly inhibits IDI-2.80 The structures of representative 
IPP analogs used to probe the IDI-2 catalysis are shown in Figure 1.13. 
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1-OPP and 2-OPP were good alternate substrates for the radical mechanism since 
they are substantially less reactive to form a carbocation but can react to generate a 
radical. For both 1-OPP and 2-OPP, it is 15 kcal/mol more endothermic to form a 
carbocation than IPP/DMAPP calculated gas-phase heats of reaction. On the other hand, 
to generate a radical species it is only 2 kcal/mol more endothermic than IPP/DMAPP. 
Incubation of 1-OPP and 2-OPP with IDI-2 resulted in covalent inhibition in a time-
dependent manner.88 Studies with vinyl thioether IPP analog showed that C4 protons 
were exchanged with solvent deuterium without isomerization.89 Taken together, these 
studies support the protonation-deprotonation mechanism of IDI-2 (Figure 1.14). 
As described, flavin does not undergo a net redox change during IDI-2 catalysis, 
and has attracted great attention to understand the role of flavin in acid-base catalysis. Liu 
and coworkers performed linear free energy studies with FMN analogs modified at 7,8 
positions with electron-donating and withdrawing groups and found negative Hammett 
plots (ρ = -2.0) and Brϕnsted plots with positive slopes (β = 0.7). The data suggested that 
flavin loses electron density and that the proton is donated to N5 of FMNred. The source 
of the proton added to the C4 of IPP still remains unclear although the authors propose 
that the proton could be derived from an H10-E22-Q154 relay (S. aureus numbering).90 
This study confirmed the general base catalysis of reduced FMN. The active site amino 
acid residues surrounding IPP (W225, H155, Q160) that are close to the C4 and C2 
carbons in IPP/DMAPP are not suitably acidic or basic to perform acid-base catalysis. 
Site-directed mutagenesis of these residues resulted in catalytically active mutant 
enzymes although their activities were substantially decreased indicating a possible acid-
base role of FMNred.92 Subsequently, Liu and coworkers determined the stereochemistry 
	   
14 
for protonation of IPP at C4 in an effort to identify the role of active site amino acids and 
FMNred in the substrate protonation step.91 The active site amino acid residue (Q154) and 
FMNred are located on the opposite side of the plane of IPP, their corresponding 
stereochemistry of protonation (E-methyl group in DMAPP) should differ. Incubation of 
E- and Z-[4-3H]-IPP with IDI-2 in D2O resulted in deuterated chiral R and S methyl 
isomers of [4-2H,3H]-DMAPP (Figure 1.15A and B) of DMAPP which can only be 
generated if the protonation occurs from the side of the flavin isoalloxazine ring. Based 
on these results, they suggest that flavin plays a central role in IPP protonation. 
Studies with the incorporation of 1-deazaFMN and 5-deazaFMN analogs into IDI-
2 revealed that IDI-2•1-deazaFMNred catalyzed IPP/DMAPP isomerization, while the 
IDI-2•5-deazaFMNred was catalytically inactive.74,93 This study indicates that N5 plays an 
important role in acid-base catalysis of IDI-2. Furthermore, in the X-ray structure of IDI-
2FMNredIPP, the distance between N5 to C4 and C2 of IPP (3.6 and 3.3 Å respectively) 
is less compared to N1 (3.9 and 4.8 Å, respectively). Taken together, these studies 
indicate that flavin plays a direct role in acid-base catalysis of IDI-2 and N5 is better 
positioned compared to N1 in the active site. 
As described above, N5 of FMNred plays a key role in acid/base chemistry, the 
pKa of N5 in neutral and anionic FMNred in solution was estimated to be ~20 which is 
only suitable to act as a base (Figure 1.16A and B).94 N1 hydrogen (pKa ~ 7) is 
deprotonated and exists in anionic form when FMNred binds IDI-2 which is stabilized by 
the nearby Lys residue. As mentioned, there is no suitable acidic amino acid residue 
(proton donor) in the active site of IDI-2 close to C4/C2 carbons of IPP. The possibility 
that FMNred could exists in N1/N5 FMNred zwitter-ionic tautomer and the pKa of N5 in 
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the zwitter-ionic FMNred has been estimated to be ~4 (Figure 1.16C) could serve as a 
proton donor.94  
We and other groups have proposed the mechanism of IDI-2 catalysis consistent 
with the zwitter-ionic FMNH2 acting as a both acid and base in the IPP and DMAPP 
isomerization (Figure 1.17). In this mechanism the N5 of FMNred zwitterion donates the 
proton to the C4/C2 of IPP/DMAPP generating a positively charged 3o carbocation in the 
active site stabilized by the negative charge on the FMNred isoalloxazine ring by HOMO-
LUMO interactions,95 and also through cation-π interactions from the near by amino acid 
residues W225 and H155 (S. shibatae numbering). In the next step, N5 in the conjugated 
base form (pKa of ~ 20) is suitable to abstract the proton from C2/C4 of the 3o 
carbocation generating DMAPP and IPP and regenerating (5,5)-FMNred zwitter-ion for 
multiple turnovers in the IDI-2 active site. The proposed mechanism also highlights that 
IDI-2 catalysis is a suprafacial 1,3-proton addition/elimination of IPP and DMAPP unlike 
IDI-1, which is an antarafacial mechanism. 
Acid/base catalysis by reduced flavins in reactions with no net redox change have 
been observed for CRTISO,96 which catalyzes the FAD-dependent cis-to-trans 
isomerization of prolycopene to all-trans-lycopene, and CRTY,97 which requires reduced 
FAD to catalyze cyclization of lycopene to β–carotene (Figure 1.18). In CRTY, the 
negative charge on the pyrimidine nucleus of FADred is proposed to stabilize the positive 
charged intermediate/transition state of lycopene similar to proposals for stabilization of 
the charged intermediate/transition state by IDI-2. CRTISO, CRTY, and IDI-2 are the 
enzymes in isoprenoid biosynthesis reported to catalyze employing neutral no redox 
flavin chemistry.  
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In 2011, Poulter and coworkers obtained evidence for the step-wise mechanism of 
IDI-2 that goes through 3o carbocationic intermediate (Figure 1.19).89 This study 
supported the step-wise mechanism in addition to the large body of evidence accumulated 
based on the studies with electrophilic mechanism-based inactivators of IDI-2 which 
suggested an existence of carbocationic intermediate or a transition state with substantial 
carbocationic character. Upon proton addition, the thiomethyl substituent at C3 of IPP 
stabilizes the tertiary carbocationic intermediate more effectively than a methyl group in 
the natural substrate IPP. This analog did not undergo isomerization and bound in an 
orientation that C4 hydrogens were exchanged with solvent deuterium. This study 
confirms the existence of a 3o carbocationic intermediate that can only be formed by a 
stepwise process. 
More recently, Poulter and coworkers determined the crystal structure of IDI-2 
from Streptococcus pneumoniae at 1.4 Å, which is the highest resolution among the 
crystal structures of IDI-2 obtained to date (Figure 1.20).98 During purification of the 
enzyme, the enzyme bound FMN cofactor was lost when protein binds Ni-NTA column 
similar to bacillus subtilis IDI-2, thereby generating apoenzyme. The apoenzyme was 
reconstituted with FMN to characterize and to study the catalysis. The substrate binding 
and catalytic constants of spIDI-2 were similar to other IDI-2 homologs. Subsequent 
kinetic characterization of the enzyme revealed that FMNH2 binds first to the enzyme 
followed by the substrate (IPP) binding and followed a sequential ordered binding 
mechanism.  
Janczak et. al. obtained further support about the ordered mechanism of spIDI-2 
where FMN binds the enzyme before IPP by undertaking detailed bisubstrate kinetic 
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studies. Inhibition studies with 5-deazaFMN and NIPP, which are the competitive 
inhibitors for FMN and IPP, supported the modified sequential ordered mechanism of 
IDI-2. Kinetic assays performed under aerobic conditions and the plots of initial 
velocities versus FMN at fixed IPP concentration have shown a sigmoidal behavior for 
FMN with a hill-coefficient of n=2. Sigmoidal behavior was not observed under strict 
anaerobic conditions when the FMN was prereduced with sodium dithionite to FMNH2.99 
Interestingly, FMN reduction by NADH in the IDI-2 active site (k = 2.8 x 10-3 s-1) was 
faster in the presence of IPP (k = 8.9 s-1). Similar experiments with sodium dithionite as a 
reductant followed a biphasic pattern of reduction, which is categorized into fast (k = 326 
s-1) and slow rates (k = 6.87 s-1) of reduction. The effect of IPP on the rate enhancements 
of IDI-2FMN reduction was proposed to be IPP induced conformational change in the 
homotetrameric IDI-2 by binding of IPP to a sub-unit other than the active site of the 
tetramer where the FMN undergoes reduction by NADH. We thought to investigate this 
problem by making a monomeric IDI-2. Creation of monomeric IDI-2 eliminates inter 
subunit-dependent mechanisms for the enhanced rate of FMN reduction. This work will 
be presented in more detail in Chapter 2 of this dissertation.  
 In 2012, Hemmi and coworkers performed a more detailed study of ssIDI-2 to 
obtain insights into the changes in solution structure caused by substrate binding. They 
observed that ssIDI-2 without a N-terminal His6-tag exists as a mixture octamers and 
tetramers with a Kd of 3.5 µM; whereas, the same enzyme with an N-terminal His6-tag is 
a tetramer.100 The tetramer-tetramer interface in the octameric protein was disrupted by 
E13R/R235E double mutation to give an active tetramer. By using SAXS, tryptophan 
fluorescence, and DLS analysis they showed that substrate (IPP) binding disrupts 
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tetramer-tetramer interface in ssIDI-2 octamer and generates a tetramer since this 
interface is required for IPP binding. Similar effect was observed for bacillus subtilis IDI-
2 (bsIDI-2) where IPP binding disrupts octamer formation.101 Few earlier studies by 
Poulter and coworkers showed that M. thermautotrophicus IDI-2102 and Synechocystis 
IDI-2103 also exists octamer-tetramer equilibrium in a concentration dependent manner 
with a Kd of 17 and 0.2 µM. There was no evidence for the formation of octamer or 
tetramer-octamer equilibrium for spIDI-2 at the concentrations tested based on both the 
gel-filtration chromatography and sedimentation equilibrium experiments. The solution 
and crystal structure of all the available IDI-2 homologs is presented in Table 1.1. 
 
 
Implications in Drug Design 
 The enzymes in the MEP pathway for the production of five carbon isoprenoid 
precursors IPP and DMAPP are novel drug targets since the human pathogens like 
Mycobacterium tuberculosis and plasmodium falciparum, the causative agents for 
tuberculosis and malaria, rely on this pathway. Other pathogenic organisms such as 
Staphylococci, streptococci, and enterococci completely rely on MVA pathway for the 
production of IPP and DMAPP. As mentioned, IDI-2 is an essential enzyme in the MVA 
pathway for the interconversion of IPP and DMAPP. Although both humans and these 
pathogenic bacteria uses the MVA pathway, humans use IDI-1 and these pathogenic 
bacteria use IDI-2 making it an attractive target for drug discovery. IDI-1 and IDI-2 are 
nonhomologous, structurally and mechanistically divergent, so development of inhibitors 
that selectively blocks IDI-2 in bacteria is a growing need for the development of 
antibacterial agents. In addition, drug resistance has been commonly observed with the 
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hospital acquired infections with the currently available antibiotics such as methicillin 
and vancomycin. Therefore, there is a growing need to develop antibacterial agents for 
drug-resistant bacterium such as methicillin- and vancomycin-resistant Staphylococcus 
aureus and Enterococci (MRSA, VRSA, and VRE). Some of the mechanism-based 
inhibitors described above commonly inhibit both IDI-1 and IDI-2 such as eIPP, oIPP, 
and so forth. Development of novel chemotherapeutic agents selective towards IDI-2 can 
be rationally designed utilizing the crystal structure of IDI-2 from pathogenic organisms. 
The crystal structure of spIDI-2 is available although it did contain the substrate IPP in 
the active site. Scaffolds that bind to the flavin in the active site is one strategy and also 
as De ruyck et. al. suggested three potential target sites near the active site of spIDI-2 to 
target with negatively charged scaffolds that bind to the arginine and lysine residues or 
sulfur binding agents that bind to the methionine. For other IDI-2 homologs from 
Staphylococci and Enterococci, the X-ray structures are yet to be solved. Nevertheless, 
homology modeling and docking studies could be a starting point to design novel 




Isopentenyl diphosphate:dimethylallyl diphosphate isomerase (IDI) catalyzes an 
essential reaction in the isoprenoid biosynthetic pathway generating the allylic 
diphosphate substrate (DMAPP) from the homoallylic diphosphate (IPP), which is a 
required step in isoprenoid biosynthesis. Two convergently evolved, structurally and 
mechanistically distinct IDI enzymes have been identified. The type 1 enzyme (IDI-1) 
requires only divalent metal ions for catalysis and uses acid/base chemistry supplied by 
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active site amino acid residues to catalyze the 1,3-proton addition/elimination of IPP to 
DMAPP. The more recently discovered IDI-2 catalyzes an identical chemical 
transformation, and requires a reduced flavin mononucleotide (FMNH2) coenzyme in 
addition to divalent metal ion for catalysis. The reaction catalyzed by IDI-2 does not 
involve a net change in the oxidation/reduction states of the substrates or the flavin 
coenzyme. The overall goal of our studies is to 1) define the general mechanistic features 
of IDI-1 and IDI-2 catalysis and to identify the role of FMNH2 in this unusual flavin-
dependent reaction, and 2) to understand the kinetics and mechanism of substrate 
binding, catalysis, and product release. This information could potentially assist in the 
development of novel inhibitors of IDI-2, as this enzyme in absent in humans, but is 
essential for the survival of several human pathogens including S. pneumoniae, S. aureus, 


















   Isopentenyl Diphosphate       Dimethylallyl Diphosphate 
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Figure 1.1. Five-carbon precursors of Isoprenoid natural products. Carbon numbering is 


















Figure 1.2. A few representative isoprenoid natural products. 
Menthol Caryophyllene Artemisinin Abscisic acid 


















































































































































MgADP + Pi + CO2PMDPMK
MgATP








































































































Figure 1.4. Crystal structures of A) E. coli IDI-1 and B) H. sapiens IDI-1. Active site of 












































Figure 1.5. E. coli IDI-1 A) the C67A mutant showing the E116-eIPP adduct B) wt 
enzyme showing the C67-eIPP adduct.52,61 
 
 











































Figure 1.7. Representative structures of IPP analogs, mechanism-based inhibitors, 
transition state mimics used to probe the mechanism of IPP isomerization. 
 
 










































Scheme 1.5. IPP and DMAPP isomerization by IDI-1. Numbering of the residues was 
based on the E. Coli enzyme. 
 
 









































































































































Scheme 1.8. IPP and DMAPP isomerization by IDI-2. 
 
 
Figure 1.9. A) Stereospecific pro R hydrogen abstraction and B) Exchangeable protons 
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Figure 1.10. Monomers from the crystal structures of A) tetrameric Sulfolobus shibatae 
(ss) IDI-2 and B) octameric Bacillus subtilis (bs) IDI-2. C) The active site of ssIDI-2 and 
D) an enlargement showing distances between N1 and N5 of FMNH2 and C2 and C4 of 


















































Figure 1.11. A) Hydrogen atom addition-abstraction and B) Protonation-deprotonation 




Figure 1.12. A) cIPP-IDI-2 reaction B) oIPP-IDI-2 reaction 
 
 































































Figure 1.15. Chiral methyl analysis of IDI-2 reaction.  
 
 


















































Neutral FMNH2 Zwitter-ionic FMNH2
A C
R = ribityl-5'-















Figure 1.17. Mechanism of IDI-2 catalysis. E represents enzyme. 
 
 
Figure 1.18. FAD-dependent cyclization of lycopene to β-carotene by CRTY with no 
FADred net redox change. 
 
 











































































                        
































Table 1.1. Solution and crystal structures of IDI-2 
 
Enzyme Solution Structure X-ray structure 
Streptococcus pneumoniae 
IDI-2 (spIDI-2)98 





Sulfolobus Shibatae IDI-2 
(ssIDI-2)75 
Octamer-Tetramer (without 












N.D Monomer per asymmetric 
unit 
P. furiosis IDI-2 (PfIDI-
2)107 
Tetramer N.D 
Synechocysis sp strain 
6803103 
Tetramer N.D 
T. kodakaraensis IDI-2 
(TkIDI-2)108 
Octamer N.D 
B. Subtilis IDI-2 (bsIDI-
2)78,101 








CONSTRUCTION OF CATALYTICALLY ACTIVE MONOMERIC 
TYPE 2 ISOPENTENYL DIPHOSPHATE:DIMETHYLALLYL 
DIPHOSPHATE ISOMERASE 	  	  
Introduction 
Protein oligomerization is a fundamental chemical process governed by the 
formation of stable noncovalent interactions across the protein subunit interfaces.109 An 
oligomer is a stable complex formed from monomeric units held together by these non-
covalent interactions. Approximately 35% of proteins in a cell exist in an oligomeric 
state.110 In some instances, active sites are located at the interface between subunits,111 
while in others cooperative motion among subunits is important for substrate binding.112 
Identifying and utilizing these interactions to manipulate protein structure and function 
can provide important insights about structure-function relationships or can provide 
proteins for structural studies by NMR spectroscopy and X-ray crystallography.113,114 
Wild-type (wt) Streptococcus pneumoniae IDI-2 is a homotetramer in solution where the 
monomers are related by a 4-fold axis of symmetry perpendicular to the plane of the sub-
units (Figure 2.1).98 In the X-ray structure of homotetrameric wt spIDI-2, the four sub-
units make identical contacts at the intersubunit interfaces. We have identified 
noncovalent interactions between monomeric subunits in the X-ray crystal structure of
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homotetrameric spIDI-298 involving amino acids at three distinct locations at the interface 
as mentioned below: 
(i) near the amino terminus  
(ii) in the middle of the polypeptide chain  
(iii) near the carboxy terminus of the monomers  
We aimed to disrupt the inter-subunit interactions to create a catalytically active soluble 
form of monomeric spIDI-2 with goals of understanding the kinetic mechanism of the 
enzyme and reducing the size of the system to improve the sensitivity of 1H, 13C, and 15N 
for NMR experiments. Mutagenesis experiments to disrupt the inter-subunit interactions 




Materials.  HEPES and NADH were purchased from Research Products 
International (RPI). Cell culture growth media, chemicals, and salts were purchased from 
Fisher Scientific, Sigma-Aldrich, and B & D. 14C-labelled IPP (50.8 µCi/µmol) was 
purchased from Perkin-Elmer. The oligonucleotide primers used for mutagenic studies 
were synthesized by the DNA/peptide synthesis HSC core facility at the University of 
Utah. 
Site-directed mutagenesis.  The gene encoding spIDI-2 contained in the plasmid 
pQE-30Xa (p-spIDI-2). The spIDI-2 gene has a hexahistidine (His6)-tag at the N-
terminus of the protein. Construction of this plasmid was previously reported.98 p-spIDI-2 
was the template for the site directed mutagenesis experiments using mutagenic primers 
for polymerase chain reaction (PCR) followed as per the QuikChange Lightning 
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mutagenesis kit (Agilent). 
Protein expression and purification.  spIDI-2 mutants containing the desired 
changes were transformed into E. coli M15pREP4 cells. The cell cultures were grown in 
MDG [LB+1% glucose] media containing 100 µg/mL ampicillin and 50 µg/mL 
kanamycin at 37 °C, 250 rpm to OD600 ~ 0.6. Protein overexpression was induced by the 
addition of isopropyl-β-D-thiogalactoside (IPTG, final concentration of 0.4 mM) that 
contained flavin mononucleotide (FMN, final concentration 40 mg/L). The cell culture 
medium was incubated for 12 h at 30 °C. The cells were then harvested by centrifugation 
(6000g, 25 min, 4 °C) and stored at -80 °C until use. The frozen cell pellet was suspended 
in lysis buffer (50 mM sodium phosphate, pH 8.0, containing 300 mM NaCl and 10 mM 
imidazole) and the cells were lysed by incubation with 10 mg lysozyme, one protease 
inhibitor tablet (Roche), and 2 mg of DNase I on ice for 30 min followed by sonication (6 
X 30 s with 1 min cooling intervals on ice). The cell lysate was centrifuged (12000 rpm, 
25 min, 4 °C) and the resulting supernatant was mixed with 10 mL of Ni-NTA Agarose 
resin (Qiagen) and loaded on to the column. Flow-through was collected, and the protein 
bound Ni-NTA agarose resin was washed with 50 mM sodium phosphate, pH 8.0, 
containing 300 mM NaCl and 20 mM imidazole containing 2M KBr until all the yellow 
color disappears. Protein was eluted with elution buffer (50 mM sodium phosphate, pH 
8.0, containing 300 mM NaCl and 250 mM imidazole) and fractions containing spIDI-2 
were pooled, concentrated with a 10 kDa MWCO filter (Centriprep, Millipore) and 
dialyzed against 10 mM Tris-HCl buffer, pH 8, containing 15% glycerol and 150 mM 
NaCl. The purity of the protein was determined by sodium dodecyl sulphate-
polyacrylamide gel (SDS-PAGE) electrophoresis. Protein concentration was determined 
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by the BCA assay (Pierce).115 
Gel-filtration chromatography.  The quaternary structures of the spIDI-2 mutants 
were estimated by gel filtration chromatography using an AKTA FPLC system with a 
Superdex 200 (Tricorn, 10/30 GL, GE) column. The column was pre-equilibrated and 
eluted at 4 oC with 50 mM potassium phosphate buffer, pH 8.0, containing 150 mM 
NaCl. Thyroglobulin (669 kDa), ferritin (440 kDa), BSA (67 kDa), ovalbumin (43 kDa), 
and ribonuclease A (14 kDa) were used as standards to calibrate the column, and the 
oligomeric state of proteins was determined based on the calibration data generated from 
the known standards mentioned above. Prior to the kinetic, CD, sedimentation, NMR, 
UV-Vis, and fluorescence thermal shift assays, the spIDI-2 proteins were purified by Ni-
NTA chromatography followed by gel-filtration chromatography purification on a 
Superdex 75 16/60 HiPrep column. 
Analytical equilibrium sedimentation.  Purified monomeric-sp-IDI-2 (m-spIDI-2) 
was dialyzed against 10 mM Tris buffer, pH 8.0, containing 150 mM NaCl and 8 mM 
TCEP to remove glycerol present in the protein storage buffer and the resulting protein 
centrifuged at 18,000 g to clarify the sample. The protein was then spun at three 
concentrations (11 µM, 5.5 µM, 2.75 µM) and three speeds (9000, 12,000, and 15,000 rpm) 
using a An-50-Ti rotor (Beckman Coulter) at 4 °C until equilibrium was established. Data 
were fit globally to an ideal single species model with a floating molecular weight using 
nonlinear least squares analysis as implemented in HeteroAnalysis.116 Buffer densities 
and protein partial specific volumes were calculated with SEDNTERP (version 1.09).117 
Circular dichroism (CD) spectroscopy.  The CD spectroscopy experiments were 
performed on a Jasco J-815 spectropolarimeter. The spectrum for wt spIDI-2 was 
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measured in 10 mM Tris buffer, pH 8.0, containing 10 % glycerol; whereas the spectrum 
for m-sp-IDI-2 was measured in 10 mM Tris buffer, pH 8.0, containing 150 mM NaCl 
and 15 % glycerol. CD spectra were recorded for 4 µM samples in a 1 cm path length 
cuvette at 25 oC as the average of three scans (0.1 nm steps) from 200 to 260 nm in with a 
signal averaging time of 1 s and a bandwidth of 1 nm. 
UV-visible assays.  UV-visible spectra for m-sp-IDI-2 were performed under 
anaerobic conditions as described.98 Apo-m-spIDI-2 was reconstituted with FMN using 
the procedure described previously, except that all washes were performed under ambient 
O2 conditions.99 The resulting m-spIDI-2FMN solution, and the substrates IPP and 
DMAPP were degassed and transferred in to anaerobic chamber. m-spIDI-2FMN was 
reduced with 8 mM Na2S2O4 and excess Na2S2O4 was removed by centrifugation using a 
10 kDa MWCO filter (Amicon Ultra) with 100 mM HEPES buffer, pH 7.0 containing 
150 mM NaCl as the wash solution. Assays were conducted in 100 mM HEPES buffer, 
pH 7.0 containing 80 µM m-spIDI-2FMN, 150 mM NaCl, 25 mM MgCl2, 2.5 mM DTT, 
and 2 mM IPP and DMAPP. Measurements were recorded on Agilent 8453 diode array 
spectrophotometer. 
Fluorescence thermal shift assays.  Tms for wt and monomeric spIDI-2 were 
measured from pH 5-10 in 50 mM buffer (pH 5.0, citric acid; pH 6–8, phosphate; pH 9.0, 
CAPSO; pH 10–11, CAPS) containing 150 mM NaCl. Assays were carried out in a 96-
well plate. Each well contained 20 µL total volume consisting of 40 x SyproOrange dye 
and 2 µM of wt or m-sp-IDI-2. The plate temperature was ramped from 27 oC to 95 oC 
and the assays were run in duplicate. 
15N-1H HSQC protein NMR studies.  Bacterial cultures for the overproduction of 
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15N-labeled wt and m-spIDI-2 were grown in 1L scale using the same IDI-2 expression 
plasmid, E. Coli strain and antibiotics described above. Wt and monomeric spIDI-2 were 
uniformly labeled with 15N by expression in minimal (M9) media using 15N-enriched 
(NH4)2SO4 (500 mg) and NH4Cl (500 mg) as a 15N-nitrogen source in 1L culture.118 Ten 
milliters of overnight LB cultures were used to inoculate 1L M9 medium for protein 
overexpression. Procedure for protein overexpression and purification was the same as 
described in protein expression and purification section. NMR spectra obtained at 25 oC 
on a 600 MHz spectrometer equipped with a cold probe. 15N-1H HSQC NMR119 spectra 
were collected for samples containing 150 µM 15N-labeled protein in 50 mM phosphate 
buffer pH 7.0 containing 10% D2O in 700 µL volume. Monomeric spIDI-2 NMR sample 
additionally contained 150 mM NaCl and 2 mM DTT. 
Enzyme activity and kinetic assays.  Isomerase activity of the spIDI-2 mutants 
was measured using the acid lability protocol.72,120 Assays under aerobic conditions with 
varied IPP and FMN were initiated by the addition of 100 nM enzyme to 100 mM 
HEPES buffer, pH 7.2, containing 150 mM NaCl, 10 mM MgCl2, and 60 – 2500 µM  
[14C]IPP (2.83 – 0.67 µCi/µmol) at 465 µM FMN and 17 – 441 µM FMN at 2 mM 
[14C]IPP (3.2 µCi/µmol) in a total volume of 50 µL. Anaerobic assays were performed in 
anaerobic chamber with 2 mM [14C]IPP (3.2 µCi/µmol), 8 mM Na2S2O4, and 0.2-238.5 
µM FMN. After 10 min at 37 °C, the reactions were stopped by addition of 200 µL of 4:1 
MeOH/HCl, followed by a incubation 10 min at 37 °C. Soluble organic products were 
extracted with 0.8 mL of ligroine and 0.4 mL of the extract was mixed with scintillation 
cocktail (Ultima Gold Cocktail, Perkin-Elmer). Radioactivity (Disintegrations per minute 
(DPM)) was counted by liquid scintillation spectrometry (TriCarb 2910TR, Perkin 
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Elmer). Kinetic assays were replicated three times under initial velocity conditions 
(<10% completion) and the data were fit with Michealis-Menten and Hill-equations 
(Table 2.3) using nonlinear regression protocols (Grafit 5.0, Erithacus Software). Blank 
samples contained H2O instead of enzyme. FMN stock concentration was determined 
using UV-vis spectroscopy with FMN extinction coefficient (λ450) of 12, 200 M-1cm-1. 
Stopped-flow kinetic assays.  FMN reduction rates were measured with a KinTek 
SF-2004 stopped-flow spectrometer equipped with a xenon arc lamp monochromater. 
The reaction buffer consisted of 100 mM HEPES, pH 7.0 containing 25 mM MgCl2 and 
150 mM NaCl at 20 °C. Measurements were performed with substrates (10 µM FMN, 2 
mM IPP), reductants (20 mM NADH or 5 mM Na2S2O4), and enzyme (10 µM IDI-
2•FMN). IDI-2•FMN complex was prepared as described in the “UV-vis assays” section. 
Changes in FMN redox state was monitored by fluorescence emission with a 530 nm 
wavelength bandpass filter (Newport Corporation) with an excitation wavelength of 420 
(IDI-2•FMN) or 450 nm (free FMN). Data were fit to a single- or double-exponential 
equation to determine pseudo-first order rate constants. Analysis was performed using 
Prism version 6.0.121 
 
 
Results and Discussion 
Analysis of the interface between subunits in homotetrameric spIDI-2.  In the 
crystal structure of wt spIDI-2, the subunits in the homotetramer are linked non-
covalently by hydrogen bonding and ionic interactions between amino acid side chains in 
one subunit with side-chains and backbone peptides in the adjacent subunit. The contact 
surfaces at the four interfaces between subunits in the homotetramer are identical, 
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forming a quaternary structure with a 4-fold axis of symmetry perpendicular to the plane 
of the subunits. Each contact surface consists of two distinct regions (Figure 2.2). 
In the first region (site 1), a loop in the subunit A (cyan), which includes amino 
acids H30 to N37, binds into a cleft between two α-helices in subunit B (gold) as shown 
in Figures 2.2 and 2.3A.  Specific polar interactions at the site 1 surface involve contacts 
between the side chains of amino acids RB159, DB186, and TB189 with the backbone 
amide moieties of amino acids LA35, SA32, and SA32/LA33, respectively, while the 
backbone amide moieties of amino acids FB183/GB184, DB186, and FB158/RB159 interact 
with side chains of amino acids HA30, SA32, and NA37, respectively (Figure 2.3B).  
In the second region (site 2), the C-terminal α-helix of one subunit in the 
homotetramer interacts with the same α-helix in the neighboring subunit. The non-
covalent attachments between the two helices consist of a combination of interactions 
between the amine group of GA324 and the side chain of EB328 (H-bonding), the side 
chains of KA327 and DB331 (ionic), and the side chains of KA330 and QB332 (H-
bonding).  These interactions are shown in Figure 2.4. All of the interactions identified in 
sites 1 and 2 are listed in Table 2.1.  The amino acids at the subunit interface surfaces are 
distant from the active site. 
Disruption of noncovalent interactions at the monomer-monomer interface.  The 
initial set of disruptions between non-covalent interactions at the interface between wt sp-
IDI-2 monomers was at site 1. The first set of mutations, H30A, S32A, N37A, and 
T189A, disrupted hydrogen bonds in HA30-FB183/GB184, SA32-DB186, NA37-
FB158/RB159, and SA32/LA33-TB189 units. The elution volume of soluble 
(H30A:S32A:N37A:T189A)-spIDI-2 on a gel filtration column was similar to that of 
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homotetrameric wt-sp-IDI-2 (Figure 2.5A and 2.5B), indicating that the removing the 
side chain-backbone hydrogen bonding interactions in site 1 did not change the 
quaternary structure of the enzyme. Two additional mutations in the site 1 region were 
studied. The R159S, D186S double mutant was a soluble homotetramer, as was the 
protein with six additional mutations (H30A, S32A N37A, R159S, D186S, T189A), 
where all of the original side chain-backbone interactions at site 1 had been altered 
(Figure 2.6).   
Next, we investigated mutations at site 2, with and without additional mutations at 
site 1. Deletion of the C-terminal α-helix (324GKLKEAKDQ333M) at site 2 in wt spIDI-2, 
as well the same deletion in a R159S:D186S site 1 double mutant background, gave 
insoluble proteins (data not shown). Furthermore, replacement of lysines K325, K327, 
and K330 in the C-terminal α-helix of (H30A:S32A: N37A:R159S:D186S:T189A)-
spIDI-2 also gave insoluble protein. These observations indicate that deletion of, or 
substantial alterations in, the C-terminal α-helix results in a loss of solubility. We then 
deleted amino acids 328EAKDQ333M in the C-terminal α-helix in 
(H30A:S32A:N37A:T189A)-spIDI-2. The resulting protein was both soluble and 
monomeric in solution (Figure 2.7), but was not active.  
In further attempts to identify a catalytically active monomer, we constructed 
single point alanine mutants and a few combinations of double point alanine mutants of 
amino acids H30, N37, and T189 in the 328EAKDQ333M-deletion background (Table 2.2). 
Among these, the individual single point alanine mutations gave catalytic active 
enzymes; whereas, the proteins with two point mutations were inactive (Table 2.2). Gel-
filtration chromatography of the H30A and T189A single mutants indicated that the 
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proteins were a mixture of monomers and tetramers in solution with the tetrameric form 
predominating (Figures 2.8A and 2.8B). In contrast, gel-filtration chromatography of the 
N37A point mutant in the 328EAKDQ333M-deletion background showed that the active 
protein was monomeric in solution with an estimated mass of 44.5 kDa (Figure 2.9). The 
monomeric state for (N37A:328EAKDQ333M-deletion)-spIDI-2 was confirmed by 
equilibrium sedimentation experiments, which gave an estimated mass of 40.5 kDa 
(Figure 2.10). The calculated mass of the protein (~39.1 kDa) corresponded to the mass 
of (N37A:328EAKDQ333M-deletion)-spIDI-2 determined by electrospray mass 
spectrometry (observed 39133.6 Da, calculated 39122.6 Da). In contrast, the N37A 
mutant without the C-terminal truncation was a catalytically active tetramer in solution 
(Figure 2.11). An overlay of chromatograms of wt and monomeric spIDI-2 clearly shows 
the difference between homotetrameric and monomeric forms of the proteins (Figure 
2.12). Both wild type and monomeric enzymes have N-terminal His6-tag, and at the 
concentrations tested these two enzymes are tetramer and monomers based on both the 
gel-filtration chromatography and sedimentation equilibrium experiments (Figure 2.13). 
Characterization of (N37A:328EAKDQ333M-deletion)-spIDI2. Steady-state kinetic 
constants were determined for monomeric (N37A:328EAKDQ333M-deletion)-spIDI2 and 
wt-spIDI-299 (Figures 2.14A, 2.14B, and 2.15) under aerobic conditions with NADH as a 
reductant and are summarized in Table 2.3. Interestingly, the kcat for monomeric spIDI-2 
is nearly same as the homotetramer; however, KmIPP was 14-fold larger, and KmFMN was 
54-fold higher for the monomer than the homotetramer! While turnover under saturating 
conditions is faster in the monomer, the homotetramer is a more efficient catalyst. The 
plot of initial velocity for different [FMN] at constant IPP was sigmoidal. A fit of the data 
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to the Hill-equation (Figure 2.14B) gave a value of n = 1.43. Sigmoidal behavior was 
seen earlier for kinetic measurements of the wild type enzyme in the presence of oxygen 
when NADH was used to reduce FMN.99 In contrast, when the kinetic studies were 
conducted in an anaerobic chamber using sodium dithionite (Na2S2O4) as the reductant, 
no sigmoidal behavior was seen (n =1, Figure 2.15).  The kcat was slightly higher than 
measured in the presence of oxygen, but KmFMNH2 was 16-fold smaller. The circular 
dichroism spectrum of (N37A:328EAKDQ333M-deletion)-spIDI-2 was similar to that for 
the wt homotetramer (Figure 2.16). Both spectra had broad minima at ~208 and ~220 nm, 
suggesting that the secondary structure of the monomer is similar to the four subunits in 
the homotetramer.  
UV-visible spectra of wt-IDI-2 from S. pneumoniae and a variety of other 
organisms are similarly distinctively different for the IDI-2FMNox, IDI-2FMNred, and 
IDI-2FMNredIPP or IDI-2FMNredDMAPP forms of the enzyme.80,82,99 The spectra for 
wt homotetrameric spIDI-2 (Figure 2.17B)99 and (N37A:328EAKDQ333M-deletion)-
spIDI-2 were virtually identical for the respective IDI-2-FMN (Figure 2.17A, 2.17B; 
orange), IDI-2FMNred (Figure 2.17A, 2.17B; red), and IDI-2FMNredIPP (Figure 
2.17A, 2.17B; cyan), and IDI-2FMNredDMAPP (Figure 2.17A, 2.17B; black) forms of 
the proteins. 
Wt spIDI-2 is more stable than the (N37A:328EAKDQ333M-deletion) mutant. 
Fluorescence thermal shift assays gave a substantially higher melting temperature for wt-
spIDI-2 (Tm ~ 69 oC) than (N37A:328EAKDQ333M-deletion)-spIDI-2 (Tm ~ 49 oC; Figure 
2.18A-C) between pH 5 – 10 (Figure 2.18D-E). Moreover, changes in pH did not 
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contribute to significant changes in Tm for both the wild type and monomeric enzymes 
(Figure 2.18D-E). 
15N-1H HSQC spectra for uniformly 15N-labeled wt and monomeric spIDI-2 are 
shown in Figure 2.19. The spectrum for the homotetramer has a limited number of cross 
peaks for the amide groups in the protein, and the dispersion is poor.  While the number 
and intensity of the cross peaks are higher in the monomer, the dispersion remains poor.  
Thus, while (N37A:328EAKDQ333M-deletion)-spIDI-2 behaves as a monomer during gel 
filtration or sedimentation equilibrium experiments, its NMR spectrum suggests that the 
protein is loosely associated in solution. 
Kinetic comparisons between spIDI-2 and (N37A:328EAKDQ333M-deletion)-
spIDI-2. We performed stopped-flow kinetic studies of the reduction of FMN by 
monomeric spIDI-2 to compare the effect of IPP on the reduction of FMN by NADH in 
the monomeric and homotetrameric forms of the enzyme. Fluorescence emission with a 
530 nm bandpass filter was used to minimize interference by NADH or dithionite. In our 
previous report,99 we suggested that substrate (IPP) binding to one of the subunits in 
native spIDI-2•FMN homotetramer induced a conformational change in the other 
subunits of the homotetramer leading to faster FMN reduction rates both by NADH and 
dithionite. We also observed a time-dependent change in the fluorescence intensity of wt 
spIDI-2•FMN upon addition of IPP that we attributed to a conformational change in the 
chromophore. Interestingly, stopped flow measurements for monomeric spIDI-2 revealed 
an enhancement in the rates of reduction of FMN similar to that seen for homotetrameric 
wt spIDI-2, in which the reduction by NADH (k = 1.64 x 10-3 s-1) is substantially faster 
when IPP is added to the enzyme (k = 0.57 s-1) (Table 2.4), and reduction by dithionite is 
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faster than by NADH. In addition, reduction of enzyme bound FMN by dithionite follows 
a biphasic double exponential pattern (Figure 2.20E) similar to that seen for the wt 
homotetramer. Unexpectedly, we also saw a time-dependent change in the fluorescence 
spectrum of monomeric spIDI-2•FMN similar to that observed for the wt homotetramer 
with a rate constant slightly faster than for the reduction by NADH, which presents a 
conundrum. We previously suggested that increases in the rates of reduction might result 
from a global conformational change in the homotetramer induced upon IPP binding to 
one of the spIDI-2•FMN subunits. However, this explanation is not valid for similar rate 
enhancements in the monomer. Moreover, an X-ray structure of wt ssIDI-2•FMNH2•IPP 
indicates that both faces of the isoalloxazine ring are shielded, by the protein on one side 
and IPP on the other, with no apparent access of NADH to FMN for a two-electron 
reduction in the ternary IDI-2•FMNH2•IPP complex.92 Perhaps a conformational change 
is induced by IPP binding to an allosteric site, although there is no evidence for this type 
on interaction in IDI-2. Alternatively, IPP might bind in the active site, induce a 












Figure 2.1. Wild type spIDI-2 crystal structure 
 
 




















Figure 2.3. Region 1. Side chains in HA30, SA32, NA37 in subunit A (cyan) interact with 
backbone amides in subunit B (gold) at residues FB183/GB184, DB186, FB158/RB159, 
respectively, while side-chains in RB159, DB186 and TB189 in subunit B (gold) interact 
with backbone amides in subunit A (cyan) at residues LA35, SA32, and SA32/LA33, 
respectively.98 A) Ribbon diagram showing helix/loop interactions. B) Interactions 








Figure 2.4. Noncovalent interactions between the C-terminal α-helices in adjacent 
subunits. GA324 (cyan) with EB328 (gold), KA327 (cyan) with DB331 (gold), and KA330 
with QB332 (gold). 
 
 
Table 2.1. Noncovalent interactions identified at the subunits interface of wt-spIDI-2. 









1 HA30 (side-chain) FB183, GB184 (peptide 
back-bone) 
3.2, 2.9 Site 1 
2 SA32 (side-chain) DB186 (peptide back-
bone) 
3.8 Site 1 
3 NA37 (side-chain) FB158, RB159 (peptide 
back-bone) 
2.6, 3.0 Site 1 
4 RA159 (side-chain) LB35 (peptide back-bone) 3.5 Site 1 
5 DA186 (side-chain) SB32 (peptide back-bone) 2.8 Site 1 
6 TA189 (side-chain) SB32, LB33 (peptide 
back-bone) 
3.2, 3.1 Site 1 
7 GA324 (amine) EB328 (side-chain) 3.4 Site 2 
8 KA327 (side-chain) DB331 (side-chain) 3.3 Site 2 
























Figure 2.5. Gel-filtration trace of A) wt-sp-IDI2, estimated molecular weight of the 
tetramer peak – 169707 Da B) H30A S32A N37A T189A-spIDI-2, estimated molecular 
weight of the tetramer peak – 164431 Da on a Superdex 200 10/300 GL column. 


















Figure 2.6. Gel-filtration trace of H30A S32A N37A R159S D186S T189A-spIDI-2 on a 
Superdex 200 10/300 GL column, estimated molecular weight of the tetramer peak – 











Figure 2.7. Gel-filtration trace of H30A S32A N37A T189A 328EAKDQM333-deleted-
spIDI-2 on a Superdex 200 10/300 GL column, estimated molecular weight of the 
tetramer peak – 168493 Da, monomer peak – 47116 Da (Calculated molecular weight of 





Table 2.2. spIDI-2 mutagenesis for monomer formation. 
 
S.No spIDI-2 mutant Solubility Structure Activity 
1 328EAKDQM333-deleted Soluble Tetramer Active 
2 328EAKDQM333-deleted 
328His6333 
Soluble Tetramer Active 
3 328EAKDQMKKA336-
deleted 328His6333 




Soluble Tetramer Active 
5 N37A-328EAKDQM333-
deleted 
Soluble Monomer Active 
6 N37A Soluble Tetramer Active 
7 H30A-328EAKDQM333-
deleted 










Soluble Monomer (major) Inactive 
10 N37A T189A-
328EAKDQM333-deleted 
Soluble Monomer (major) Inactive 
11 H30A N37A T189A-
328EAKDQM333-deleted 
Soluble Monomer (major) Inactive 
12 H30A S32A N37A T189A Soluble Tetramer Active         
13 H30A S32A N37A T189A-
328EAKDQM333-deleted 
Soluble Monomer (major)/ 
Tetramer (minor) 
Inactive 
14 H30A S32A N37A T189A-
328EAKDQM333-deleted 
328His6333 
Soluble Monomer (major –
less % to 13) 
Inactive 









16 H30A S32A N37A R159S 
D186S T189A 
Soluble Tetramer Inactive 
17 H30A S32A N37A R159S 
D186S T189A-
328EAKDQM333-deleted 
Soluble Monomer Inactive 
18 324GKLKEAKDQM333-
deleted 
Insoluble - - 
19 R159S D186S 
324GKLKEAKDQM333-
deleted 
Insoluble - - 
20 H30A S32A N37A R159S 
D186S T189A K325D K327D 
K330D 
Insoluble - - 




Table 2.2. continued 
22 H30D S32D N37D T189D Less 
soluble 
Tetramer/Monomer  Less 
Active 








24 N37A D186A Soluble Trimer/Tetramer  Active 
25 N37A D186A 
328EAKDQM333-deleted 








































Figure 2.8. A) Gel-filtration trace of H30A 328EAKDQM333-deleted-spIDI-2, 
Estimated molecular weight of the tetramer peak – 152289 Da, monomer peak – 41151 
Da B) T189A 328EAKDQM333-deleted-spIDI-2, estimated molecular weight of the 
























Figure 2.9. Chromatography of (N37A:328EAKDQ333M-deletion)-spIDI-2 on a Superdex 
200 analytical 10/300 GL column. The estimated mass of the protein (44505 Da) is 











Figure 2.10. Analytical equilibrium sedimentation analyses of the A) monomeric 
(N37A:328EAKDQ333M-deletion)-spIDI-2 B) tetrameric wild type spIDI-2 and the 
corresponding ideal single species global fits. Bottom, residual differences between the 
data and fits. Representative data are shown for 15,000 rpm and three concentrations. The 
observed molecular weight of the monomer was 40,529 Da (MWobs/MWcalc = 1.04) 













































































Figure 2.11. Gel-filtration trace of N37A spIDI-2 on a Superdex 200 10/300 GL column, 
Estimated molecular weight of the tetramer peak – 161323 Da (Calculated molecular 




Figure 2.12. Overlay gel-filtration traces of wt homotetrameric and monomeric spIDI-2 






























~ 45 kDa 
~ 152 kDa 
~ 45 kDa 










15N labeled protein-NMR 
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Figure 2.14. a) Michaelis-Menten plot of N37A 328EAKDQM333-deleted-spIDI-2 
Monomer (Varied IPP and constant FMN) b) Hill-Equation plot (Varied FMN and 










kcat = 1.08 ± 0.09 s-1 
Km FMN = 131 ± 19 µM 
n = 1.43 ± 0.17 
at [IPP] = 2 mM 	  
Hill equation 
Km IPP = 572 ± 34 µM 
kcat = 1.31 ± 0.04 s-1 










Figure 2.15. Varying FMN at saturating IPP of N37A 328EAKDQM333-deleted-spIDI-2 














Km IPP = 8.01 ± 0.54 µM 
kcat = 2.11 ± 0.08 s-1 
at [IPP] = 2 mM 
n =  1.02 ± 0.04 
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IPP 40.8 ± 5.6 0.983 ± 
0.078 
292 ± 39g 
















  FMN 5.12 ± 0.73 x 
10-2 
  
aAssay conditions: 100 mM HEPES, pH 7.0, containing 150 mM NaCl, 10 mM MgCl2, 
20 mM NADH, 2 mM DTT, 0.14 mg/mL BSA, and 100 nM (N37A:328EAKDQ333M-
deletion)-spIDI-2 at 37 ºC. b60-2500 µM IPP, 0.46 mM FMN. c17–441 µM FMN, 2 mM 
IPP. dApparent values determined at saturating levels of the second substrate. e8 mM 






































Figure 2.17. UV-vis spectra of various forms of the IDI2-bound FMN. Reaction 
conditions are given in the Methods section. (A) Monomeric spIDI-2 (B) wt-spIDI-2.99 
Orange, red, cyan, black dotted curves represent IDI2FMNox, IDI2FMNred, 

























































Figure 2.18. Fluorescence thermal shifts assays for wt and monomeric spIDI-2. (A) 
Thermograms for the proteins in 50 mM buffer (pH 5.0 citric acid; pH 6–8 phosphate; pH 
9.0 CAPSO; pH 10–11 CAPS); pH 5 (brown), pH 6 (red), pH 7 (orange), pH 8 (cyan), 
pH 9 (blue), pH 10 (green). (B and C) Negative derivatives of the thermograms (-dF/dT) 



































































         
 
 















































































































































Figure 2.19. 15N-1H HSQC comparison of (A)15N-labeled monomeric and (B) 15N-



















































































































































Table 2.4. Rates of reduction for FMN, monomeric spIDI-2•FMN, and monomeric 









FMN à FMNH2 
Dithionite 62.4 ± 0.4 
NADH 3.4 x 10-3 ± 3.0 x 10-5 
 
spIDI-2•FMN à spIDI-2•FMNH2 
Dithionite 50.2 ± 0.9 




Dithionite 32.4 ± 2.3 (k1) 
0.67 ± 4.7 x 10-3 (k2) 
NADH 0.57 ± 0.018 
 













Figure 2.20. Stopped-flow kinetic figures. Black lines represent the average of replicates. 
Excitation wavelength 420 nm for MonomerFMN and 450 for free FMN. Fluorescence 

















Syringe 1 = 10 μM FMNox




















Syringe 1 = 10 μM FMNox
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Figure 2.20 continued. 
 
Syringe 1 = 10 μM Monomer!FMNox+ 2 mM IPP



















Syringe 1 = 10 μM Monomer!FMNox+ 2 mM IPP














0 0.01 0.02 0.03 0.04 0.05
Syringe 1 = 10 μM Monomer!FMNox+ 5 mM Dithionite
Syringe 2 = 2 mM IPP + 5 mM Dithionite
15 replicates
Syringe 1 = 10 μM Monomer!FMNox+ 5 mM Dithionite



























































Syringe 1 = 10 μM Monomer!FMNox+ 2 mM IPP



















Syringe 1 = 10 μM Monomer!FMNox+ 2 mM IPP
Syringe 2 = 20 mM NADH
20 replicatesE F
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Figure 2.20 continued. 
Syringe 1 = 10 μM Monomer!FMNox+ 5 mM Dithionite
























Syringe 1 = 10 μM Monomer!FMNox+ 5 mM Dithionite
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Syringe 1 = 10 μM Monomer!FMNox+ 5 mM Dithionite
























Syringe 1 = 10 μM Monomer!FMNox+ 5 mM Dithionite
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SITE-SELECTIVE SYNTHESIS OF 15N- AND 13C-ENRICHED  
FLAVIN MONONUCLEOTIDE COENZYME  




Flavins, derived from the Latin word flavus (yellow), are widely spread in nature, 
where they serve as coenzymes in a wide variety of biological processes. Three different 
types of flavins are found in nature (Figure 3.1). Riboflavin (vitamin B2) is the 
biosynthetic precursor for flavin mononucleotide (FMN) and flavin adenine dinucleotide 
(FAD), which are the biologically active coenzymes. Typically, flavin coenzymes 
mediate one and two-electron redox reactions,122,123 but they serve in other roles such as 
electrophilic and nucleophilic substitution,124,125 flavin-based (BLUF) blue light 
photoreceptors,126 DNA repair,127-129 signal transduction, and light sensing.130 
Additionally, many flavoenzymes are targets for drug development,98,131 where a  
thorough understanding of structure and mechanism could facilitate the design of novel 
lead compounds as therapeutic agents. There are more than 100,000 entries in the 
National Center for Biotechnology Information database related to flavoproteins, which 
constitute a large family with novel functions.122,132 Isotopically enriched flavins and 
flavin analogs are useful probes for studying the structure and function of the coenzyme
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in flavin-dependent processes. A few notable applications include investigations of flavin 
transport and metabolism133, elucidation of the mechanisms of flavoenzyme-catalyzed 
reactions where the cofactor is involved in the chemistry of enzyme catalysis,134-137 and 
studies of the dynamics of light receptors.138 Flavins uniformly enriched with 15N and 13C 
are employed to improve the NMR signal sensitivity, particularly when the cofactors are 
bound to proteins. Selective 15N and 13C enrichment is used to enhance signals for 
specific atoms of interest in an unlabeled background and for individual peak 
assignments.139 Site-specifically 15N and 13C enriched flavins are highly useful for 
unequivocal band assignments in NMR, IR, and Raman spectroscopy.140 13C-FAD 
isotopologues were used to study the BLUF-domain protein photoreceptor141 and both 13C 
and 15N-FMN were used to investigate flavin-protein interactions in flavocytochrome 
b2.142 
Several flavin analogues have been used as mechanistic probes for the active sites 
of flavoenzymes (Figure 3.2). Flavins are typically bound noncovalently in the active 
site, and methods have been developed to remove the enzyme bound flavin in order to 
reconstitute the proteins with flavin analogs. In the fully oxidized state, flavins exhibit 
strong UV-vis signatures with maxima at ~370 nm and ~ 450 nm. The UV-vis spectra of 
flavin probes often change for free and protein bound forms. For example, the reactivity 
of 8-chloroflavin towards sulfur nucleophiles has been used to identify cysteine thiol 
residues in the active site near 8-position of the bound analog.143 The spectral changes 
upon conversion of 8-chloro to 8-mercaptoflavin are dramatic as they have absorption 
maxima at ~ 470 nm and 8-mercaptoflavins have been used to study the redox processes 
of flavin in various flavin-dependent enzymes.144 Similarly, 4-thioflavins have been used 
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to study the environment around the C4 carbonyl of flavin. It was found that 4-thioflavins 
are reactive towards both nucleophiles and electrophiles.145 1-carba-1-deaza- and 5-carba-
5-deazaflavins (1-deaza and 5-deaza flavins) are commonly used mechanistic probes.143 
3H-, 17O-, 18O-, 15N- and 13C-flavin isotopologues are used to study the mechanism and 
structure of flavins in flavoenzyme-catalyzed reactions by standard spectroscopic 
techniques.146-148  5-Deazaflavins have been used to determine the existence of covalent 
intermediates and radical flavin intermediates in a variety of reactions. The covalent 
adducts can be isolated and detected by conventional spectroscopic techniques.149 
Synthetic methods, biosynthetic methods, and a combination of the two have been 
used to insert 15N and 13C-labels into riboflavin.150 The Tishler condensation of o-
aminoazo compounds with barbituric acid is a classic chemical approach for synthesis or 
riboflavin.151 GTP and ribulose 5-phosphate are precursors for biosynthesis of riboflavin 
through the sequence of steps catalyzed by GTP cyclohydrolase II, lumazine synthase, 
and riboflavin synthase.152 Recently, Fischer and coworkers reported an in vivo 
biotransformation method using an engineered bacterial strain to synthesize 15N, 13C, 17O, 
and 18O-labeled flavins from isotopically labeled precursors.153 In another report, Kohen 
and coworkers reported an enzymatic synthesis of 3H-, 15N-, and 13C-labeled flavins from 
commercially available isotope-labeled riboflavin precursors.154 In this chapter, I describe 
a combination of chemical and biotransformation steps for labeling nitrogen and carbon 








Materials.  Cell culture growth media, salts, and chemicals were purchased from 
Fisher Scientific, B&D, and Sigma-Aldrich. Na15NO2 (98% 15N) was purchased from 
Sigma-Aldrich, 15N2-Urea (98%+ 15N2), and 13C(2)-diethyl malonate (99% 13C) were 
purchased from Cambridge Isotope Laboratories (CIL), 14C-labelled IPP was purchased 
from Perkin-Elmer, Homo sapiens (hs) riboflavin kinase plasmid (HS_RFK_EC_1_pQE-
T7) was purchased from Qiagen.  
Anhydrous reaction conditions were employed using anhydrous solvents under a 
nitrogen atmosphere in oven-dried glassware (100 °C). Anhydrous methanol (MeOH), 
ethyl alcohol (ethanol) was obtained by passing through a column of activated alumina.
 
Purification of the 5, 6, [15N]6 was carried out using the silica gel flash column 
chromatography with silica gel (230−400 mesh, 60 Å). EMD Silica Gel 60 Å F254 TLC 
aluminum plates were for the thin-layer chromatographic analysis, and the spots were 
visualized under UV light. All the 1H, 13C, and 31P NMR spectra were recorded at 25 °C, 
and chemical shifts were reported in δ ppm (parts per million) values. 1H NMR spectra 
were recorded at 300 and 500 MHz and were referenced using CD3OD, d6-DMSO, and 
D2O NMR solvents. 13C NMR spectra were recorded at 75 and 125 MHz, and 31P NMR 
was recorded at 121 MHz. 13C and 31P NMR spectra recorded in D2O were unreferenced. 
HRMS-ESI data were recorded on LC-TOF and LTQ-FTMS mass spectrometers. HPLC 
purification of crude isotopically labeled FMN mixture was applied to a reverse phase 
column (XBridge C18, Waters, 19 × 100 mm) that had been equilibrated with 100% 
ammonium bicarbonate (NH4HCO3). NH4HCO3 – acetonitrile (ACN) gradient run was 
performed for a total run time of 45 min at a flow rate of 2 mL/min (rt). The retention 
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time for FMN was 28.5 min. Fractions were combined, lyophilized and stored at −80 °C. 
 Barbituric acid (3).  In a 50 mL round bottomed flask, sodium (250 mg, 10.8 
mmol) was carefully added to 15 mL of ethanol. After the sodium metal had been 
consumed, diethyl malonate (2, 1.65 mL, 10.8 mmol) was added followed by urea (1, 
0.65 g, 10.8 mmol). The stirred mixture was heated at reflux for 7 h in an oil bath, during 
which time a white solid precipitated. The reaction was acidified with 13 mL of H2O and 
1.2 mL of 12 N HCl to a pH ~ 4. The clear solution was then filtered and cooled in an ice 
bath. The precipitate was removed by filtration and washed with 1 mL of cold H2O to 
give 0.99 g (72%) of a white solid155; 1H NMR (300 MHz, d6-DMSO) δ ppm 11.13 (s, 
2H), 3.46 (s, 2 H); 13C NMR (300 MHz, d6-DMSO) δ ppm 168, 151.8; GC-MS [M]+ 
calculated for C4H4N2O3 128.09, observed 128.1. 
[5-13C]Barbituric acid ([5-13C]3).  Following the procedure described for 3; 
sodium (200 mg, 8.699 mmol) in 5 mL ethanol, diethyl [2-13C]malonate ([2-13C]2) (0.5 
mL, 6.204 mmol), and 1 (0.372 g, 6.204 mmol) were combined to give 0.54 g (68%) of a 
white solid; 1H NMR (500 MHz, d6-DMSO) δ ppm 11.09 (s, 2H), 3.47 (d, 2H, 1JC-H = 
130 Hz) ppm; 13C NMR (500 MHz, d6-DMSO) δ ppm 167.3 (d, 1JC-C = 39.18 Hz), 
151.31. HRMS (ESI-) calculated for 13C1C3H3N2O3 [M-H]- (m/z) = 128.0183, found 
128.0182. 
[1,3-15N2]Barbituric acid ([1,3-15N2]3).  Following the procedure described for 3; 
sodium (90 mg, 3.91 mmol) in 5 mL ethanol, 2 (0.5 mL, 3.223 mmol), and [1,3-15N2]1 
(0.20 g, 3.22 mmol) were combined to give 0.275 g (66%) of a white solid; 1H NMR 
(400 MHz, d6-DMSO) δ ppm 11.12 (d, 2H, 1JN-H = 92 Hz), 3.46 (s, 2H); 13C NMR (400 
MHz, d6-DMSO) δ ppm 167.4 (d, 1JC-N = 11 Hz), 151.3 (t, 1JC-N = 18.1 Hz). HRMS (ESI-) 
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calculated for C4H315N2O3 [M-H]- (m/z) =129.0090, observed 129.0090. 
N-Ribityl 3,4-dimethyl aniline (5).  In a 250 mL round bottomed flask, 3,4-
dimethyl aniline (4) (2.06 g, 17 mmol), D-ribose (7.9 g, 53.0 mmol), and sodium 
cyanoborohydride (2.07 g, 33.0 mmol) were dissolved in 100 mL of methanol. The 
mixture was heated at reflux for 48 h with stirring. Solvent was removed under reduced 
pressure, and the residue was dissolved in 1 M HCl (40 mL) and swirled. A saturated 
solution of NaHCO3 was added and the mixture was extracted with ethyl acetate (6 x 35 
mL). The combined organic layers were washed with brine and dried over MgSO4. 
Solvent was removed under reduced pressure to give 3.81 g (88%) of a white solid156; 1H 
NMR (300 MHz, d3-MeOD) δ ppm 6.88 (d, 1H, J= 9 Hz), 6.55 (d, 1H, J= 2.3 Hz), 6.47 
(dd, 1H, J= 2.4, 8 Hz), 3.91 (ddd, 1H, J= 8, 6.1, 3.5 Hz), 3.81-3.6 (m, 4H), 3.43 (dd, 1H, 
J= 12.8, 3.5 Hz), 3.08 (dd, 1H, J=12.8, 8 Hz), 2.17 (s, 3H), 2.12 (s, 3H); 13C NMR (300 
MHz, d3-MeOD) δ ppm 148.2, 138.1, 131.2, 126.9, 116.9, 112.7, 75, 74.5, 72.2, 64.8, 
48.2, 20.2, 19. 
N-Ribityl-2-phenylazo-4,5-dimethyl aniline (6).  Aniline (0.22 g, 2.36 mmol), 12 
N HCl (0.66 mL) and H2O (1.55 mL) were mixed in a 50 mL round bottom flask and 
allowed to stir at 0 oC for 10 min, followed by slow addition of solid NaNO2 (0.163 g, 
2.36 mmol) in small portions. The solution was maintained at 0 oC for 30 min. In a 
second 50 mL round bottomed flask, N-ribityl 3,4-dimethyl aniline 5 (0.5 g, 1.95 mmol) 
was dissolved in 4 mL of H2O followed by the addition of 0.7 mL of 12 N HCl and 0.66 
g (8.04 mmol) of sodium acetate. The mixture was cooled to -5 oC, the solution of 
diazotized aniline was added, and the resulting solution was stirred at -9 to -5 oC for 1 h 
and at 0 oC for 2 h. After warming to 20 oC, a solution of 0.33 g (4.02 mmol) of sodium 
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acetate in 2.5 mL H2O was slowly added to maintain pH ~ 3 and the temperature at 17-20 
oC. The resulting mixture was allowed to stir at 22-25 oC for 17 h to give a dark orange 
suspension. The solid was removed by filtration and purified by flash chromatography 
(1:10 v/v MeOH/DCM) to give 0.67 g (95%) of a orange solid157; Rf 0.35 (1:10 v/v 
MeOH/DCM); 1H NMR (300 MHz, d3-MeOD) δ ppm 7.82-7.79 (m, 2H), 7.52 (s, 1H), 
7.47-7.42 (m, 2H), 7.36-7.32 (m, 1H), 6.72 (s, 1H), 4.05-3.97 (m, 1H), 3.82-3.61 (m, 
5H), 3.39 (dd, 1H, J = 13.1, 7.7 Hz), 2.28 (s, 3 H), 2.22 (s, 3 H); LC-MS [M+Na]+ 
calculated for C19H25N3O4Na 382.92, observed 382.2. 
[15N]-N-ribityl-2-phenylazo-4,5-dimethyl aniline ([15N]6).  Following the 
procedure described for 6; aniline (0.109 g, 1.18 mmol), 0.33 mL of 12 N HCl, 0.77 mL 
of H2O and Na15NO2 (0.0825 g, 1.18 mmol) were combined to prepare the corresponding 
diazonium salt. The diazonium salt was added to 5 (0.25 g, 0.979 mmol) to give 0.34 g 
(97%) of an orange solid; Rf  0.35 (1:10 v/v MeOH/DCM); 1H NMR (300 MHz, d3-
MeOD) δ ppm 7.85-7.81 (m, 2H), 7.53 (s, 1H), 7.49-7.44 (m, 2H), 7.39-7.34 (m, 1H), 
6.75 (s, 1H), 4.05-3.99 (m, 1H), 3.84-3.61 (m, 5H), 3.39 (dd, 1H, J = 13.2 Hz, 7.7 Hz), 
2.29 (s, 3H), 2.23 (s, 3H); 13C NMR (300 MHz, d3-MeOD) δ ppm 154.5 (d, JC-N = 5.1 
Hz), 144.1, 143.8, 136.7, 131.2 (d, JC-N = 6.75 Hz), 130.4, 130.2, 125.2 (d, JC-N = 2.92 
Hz), 123 (d, JC-N = 3.75 Hz), 114.3, 74.7, 72.5, 64.8, 46, 20.8, 18.9; HRMS (ESI+) 
calculated for C19H25N215N1O4Na [M+Na]+ (m/z) = 383.1713, found 383.1726. 
Riboflavin (7).  To N-ribityl-2-phenylazo-4,5-dimethyl aniline 6 (100 mg, 0.278 
mmol) in a 10 mL round bottomed flask, 2 mL of n-butanol, barbituric acid 3 (56.5 mg, 
0.44 mmol) and 0.5 mL of AcOH was added. The mixture was stirred and heated to 
reflux for 5 h, stirred for additional 1 h in an ice-bath, and then filtered. The solid on the 
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filter was washed with hot H2O and methanol to give 62.5 mg of a crude yellow solid; 
HRMS (ESI+) calculated for C17H21N4O6 [M+H]+ (m/z) 377.1461, observed 377.1463. 
[5-15N]Riboflavin ([5-15N]7).  Following the procedure described for 7; [5-15N]6 
(100 mg, 0.278 mmol), 2 mL of n-butanol, 3 (56 mg, 0.44 mmol) and 0.5 mL of AcOH 
were combined to give 85.5 mg of a crude yellow solid (75% pure as determined by 
HPLC); HRMS (ESI+) calculated for C17H20N315NO6Na [M+Na]+ (m/z) 400.1251, 
observed 400.1255. 
[5-15N, C4a-13C]Riboflavin ([5-15N, 4a-13C]7).  Following the procedure 
described for 7; [15N]6 (54.6 mg, 0.1515 mmol), 1.5 mL of n-butanol, [5-13C]3 (40 mg, 
0.3121 mmol) and 0.3 mL of AcOH were combined to give 42 mg of a crude yellow 
solid (59% pure as determined by HPLC); HRMS (ESI+) [M+H]+ calculated for 
C1613CH21N315NO6 379.1460, observed 379.1459. 
[4a-13C]Riboflavin ([4a-13C]7).  Following the procedure described for 7; 6 (60 
mg, 0.166 mmol), 1.5 mL of n-butanol, [5-13C]3 (40 mg, 0.3121 mmol) and 0.3 mL of 
AcOH were combined to give 50 mg of a crude yellow solid (80% pure as determined by 
HPLC); HRMS (ESI+)  [M+Na]+ calculated for C1613CH20N4O6Na 400.1309, observed 
400.1286. 
[1,3-15N2]Riboflavin ([1,3-15N2]7).  Following the procedure described for 7; 6 
(100 mg, 0.2766 mmol), 1.5 mL of n-butanol, [1,3-15N2]3 (56 mg, 0.43 mmol) and 0.3 
mL of AcOH were combined to give 76.8 mg of a crude yellow solid (86% pure as 
determined by HPLC); HRMS (ESI+) [M+H]+ calculated for C17H21N215N2O6 379.1396, 
observed 379.1401. 
5-Deazariboflavin (8).  5-Deazariboflavin (88% pure as determined by HPLC) 
	   
82 
was synthesized as previously described156 and was a generous gift from Dr. Seoung 
Ryoung-Choi. HRMS (ESI+) [M+H]+ calculated for C18H22N3O6 376.1503, observed 
376.1505. 
Expression and purification of homo sapiens (hs) riboflavin kinase (RFK).  E. coli 
BL21 (DE3) cells were transformed with homo sapiens (hs) riboflavin kinase plasmid 
(HS_RFK_EC_1_pQE-T7) containing the gene for RFK with a N-terminal His6 affinity 
tag (Qiagen). Starting from a single colony, the cells were grown in 1L of MDG [Luria 
Broth158 +1% glucose] containing 34 µg/mL kanamycin at 37 °C, 250 rpm to OD600 ~ 
0.6. Expression of the protein was induced by addition of isopropyl-β-D-thiogalactoside 
(IPTG, final concentration of 1 mM). Incubation was continued for 4 h at 37 °C. The 
cells were harvested by centrifugation (6000g, 25 min, 4 °C) and stored at -80 °C until 
used. A frozen cell pellet was suspended in lysis buffer (50 mM sodium phosphate, pH 
8.0, containing 300 mM NaCl and 10 mM imidazole) and the cells were lysed by 
incubation with lysozyme, one protease inhibitor tablet (Roche), and DNase I (2 mg) on 
ice for 30 min followed by sonication (6 cycles of 30 s, 1 min cooling on ice). The cell 
lysate was centrifuged (12000 rpm, 25 min, 4 °C) and the resulting supernatant was 
mixed with 10 mL of Ni-NTA Agarose resin (Qiagen) and loaded on to a column. The 
resin was washed with 80 mL of 50 mM sodium phosphate buffer, pH 8.0, containing 
300 mM NaCl and 20 mM imidazole and then eluted 50 mM sodium phosphate buffer, 
pH 8.0, containing 300 mM NaCl and 500 mM imidazole. Fractions were analyzed by 
SDS gel electrophoresis and those containing RFK were pooled, concentrated by 
centrifugation with a 10 KDa MWCO filter (Centriprep, Millipore), and dialyzed against 
10 mM Tris-HCl buffer, pH 8, containing 10% glycerol. Protein concentration was 
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determined by the BCA assay (Pierce).  
FMN.  In a 100 mL round bottomed flask, crude riboflavin 7 (25 mg, 0.066 mmol, 
0.66 mM), ATP (275.57 mg, 0.5 mmol, 5 mM) were incubated with riboflavin kinase 
(18.84 mg, 1 µmol, 10 µM) in 100 mL of buffer (100 mM 3-(N-
morpholino)propanesulfonic acid (MOPS), pH 7.9) containing 5 mM MgCl2 for 12 h at 
30 oC. After incubation, the enzyme was removed by filtration (Millipore Centricon, 
10000 molecular weight cutoff (MWCO)). The solvent was then removed under 
lyophilization and the solid was purified on high performance liquid chromatography 
equipped with RP-C18 column to give 19.2 mg of a yellow solid; 1H NMR (300 MHz, 
D2O) δ ppm 7.69 (s, 1H), 7.48 (s, 1H), 4.97 (t, J=11.7 Hz, 1H), 4.6 (d, J= 13.8 Hz, 1H), 
4.34-4.31 (m, 1H), 4.11-3.97 (m, 4H), 2.45 (s, 3H), 2.31 (s, 3H); 13C NMR (75 MHz, 
D2O) δ ppm 160.8, 157.8, 150.8, 149.8, 139.6, 134.2, 133.7, 131.6, 130.3, 117.1, 72.6, 
71.4 (d, JC-P = 7.95 Hz), 69.3, 66, 47.6, 20.9, 18.7; 31P NMR (121 MHz, D2O) δ ppm 
2.72; HRMS (ESI-) calculated for C17H20N4O9P (M - H)- m/z = 455.0973, found 
455.0971. 
[5-15N]FMN.  Following the procedure described for FMN; Crude [5-15N]7 (10 
mg, 0.0265 mmol, 0.53 mM) and ATP (137.785 mg, 0.25 mmol, 5 mM) were incubated 
with riboflavin kinase (9.423 mg, 0.5 µmol, 10 µM)  in 50 mL of buffer containing 5 mM 
MgCl2 and purified by HPLC to give 8.94 mg (98 %) of a yellow solid; 1H NMR (500 
MHz, D2O) δ ppm 7.77 (s, 1H), 7.61 (s, 1H), 5.04 (t, J=10 Hz, 1H), 4.69 (d, J= 15 Hz, 
1H), 4.39-4.36 (m, 1H), 4.16-3.99 (m, 4H), 2.51 (s, 3H), 2.38 (s, 3H); 13C NMR (125 
MHz, D2O) δ ppm 163.5 (d, 2JC-N = 6.3 Hz), 160.3, 153.3, 152.4, 142, 136.8, 136.4 (d, JC-
N = 4.28 Hz), 134.2, 132.9 (d, 2JC-N = 7.56 Hz), 119.5, 75, 73.8 (d, JC-P = 7.56 Hz), 71.8, 
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50.1, 23.4, 21.2; 31P NMR (121 MHz, D2O) δ ppm 1.92; HRMS (ESI-) calculated for 
C17H2014N315NO9P (M-H)- m/z = 456.0938, found 456.0950. 
[5-15N, 4a-13C]FMN.  Following the procedure described for FMN; Crude [5-15N, 
4a-13C]7 (10 mg, 0.0264 mmol, 0.53 mM) and ATP (137.785 mg, 0.25 mmol, 5 mM) 
were incubated riboflavin kinase (9.423 mg, 0.5 µmol, 10 µM) in 50 mL of MOPS buffer 
containing 5 mM MgCl2 and purified by HPLC to give 7.19 mg (98 % yield) of a yellow 
solid; 1H NMR (500 MHz, D2O) δ ppm 7.76 (s, 1H), 7.60 (s, 1H), 5.03 (t, J = 10 Hz, 
1H), 4.68 (d, J = 15 Hz, 1H), 4.38-4.35 (m, 1H), 4.15-3.97 (m, 4H), 2.49 (s, 3H), 2.37 (s, 
3H); 13C NMR (125 MHz, D2O) δ ppm 163.6 (dd, 1JC-C = 76.1 Hz, 2JC-N = 7.56 Hz), 
160.3, 153.2, 152.4 (d, 1JC-C = 55.44 Hz), 142, 136.8, 136.4 (d, JC-N = 3.78 Hz), 134.2 (d, 
3JC-C = 6.17 Hz), 132.9 (t, 3JC-C = 6.3 Hz), 129, 119.5, 75, 73.8 (d, JC-P = 7.56 Hz), 71.8, 
68.8, 50, 23.3, 21.2; 31P NMR (121 MHz, D2O) δ ppm 1.95; HRMS (ESI-) calculated for 
C1613CH2014N315NO9P (M - H)- m/z = 457.0972, found 457.0971.  
[4a-13C]FMN.  Following the procedure described for FMN; Crude [4a-13C]7 (10 
mg, 0.0265 mmol, 0.53 mM) and ATP (137.785 mg, 0.25 mmol, 5 mM) were incubated 
with riboflavin kinase (9.423 mg, 0.5 µmol, 10 µM)  in 50 mL of buffer containing 5 mM 
MgCl2 and purified by HPLC to give 9.38 mg (97 % yield) of a yellow solid; 1H NMR 
(500 MHz, D2O) δ ppm 7.74 (s, 1H), 7.56 (s, 1H), 5.01 (t, J = 10 Hz, 1H), 4.65 (d, J = 15 
Hz, 1H), 4.38-4.34 (m, 1H), 4.13-3.98 (m, 4H), 2.48 (s, 3H), 2.35 (s, 3H); 13C NMR (125 
MHz, D2O) δ ppm 163.4 (d, 1JC-C = 76.86 Hz), 160.3, 153.2, 152.3 (d, 1JC-C = 55.44 Hz), 
142, 136.7, 136.3, 134.1 (d, 3JC-C = 6.04 Hz), 132.8 (d, 3JC-C = 6.1 Hz), 128.8, 119.5, 75, 
73.8 (d, JC-P = 7.2 Hz), 71.8, 68.6, 50, 23.3, 21.2; 31P NMR (121 MHz, D2O) δ ppm 1.85; 
HRMS (ESI-) calculated for C1613CH20N4O9P (M - H)- m/z = 456.1001, found 456.0995. 
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[1,3-15N2]FMN.  Following the procedure described for FMN; Crude [1,3-15N2]7 
(10 mg, 0.0265 mmol, 0.53 mM) and ATP (137.785 mg, 0.25 mmol, 5 mM) were 
incubated with riboflavin kinase (9.423 mg, 0.5 µmol, 10 µM)  in 50 mL of buffer 
containing 5 mM MgCl2 and purified by HPLC to give 10.66 mg (> 98 % yield) of a 
yellow solid; 1H NMR (500 MHz, D2O) δ ppm 7.75 (s, 1H), 7.57 (s, 1H), 5.02 (t, J = 10 
Hz, 1H), 4.67 (d, J= 15 Hz, 1H), 4.39-4.36 (m, 1H), 4.17-3.99 (m, 4H), 2.50 (s, 3H), 2.36 
(s, 3H); 13C NMR (125 MHz, D2O) δ ppm 163.4 (d, JC-N = 13.86 Hz), 160.3 (t, JC-N = 
11.0 Hz), 153.3, 152.3 (d, JC-N = 7.93 Hz), 142, 136.8, 136.3, 134.1, 132.9, 119.5, 75, 
73.8 (d, JC-P = 7.56 Hz), 71.8, 68.8, 50.1, 23.5, 21.2; 31P NMR (121 MHz, D2O) δ ppm 
1.9; HRMS (ESI-) calculated for C17H2014N215N2O9P (M - H)- m/z = 457.0909, found 
455.0913. 
5-deazaFMN (9).  Following the procedure described for FMN; crude 8 (12 mg, 
0.032 mmol, 0.53 mM) and ATP (137.785 mg, 0.25 mmol, 5 mM) were incubated with 
riboflavin kinase (9.423 mg, 0.5 µmol, 10 µM) in 50 mL of buffer containing 5 mM 
MgCl2 and purified by HPLC to give 13 mg (> 98% yield) of a yellow solid;159 1H NMR 
(500 MHz, D2O) δ ppm 7.78 (s, 1H), 7.45 (s, 1H), 7.03 (s, 1H), 4.27-3.97 (m, 7H), 2.3 (s, 
3H), 2.12 (s, 3H); 13C NMR (125 MHz, D2O) δ ppm 164.7, 161, 158.7, 152.1, 143.6, 
141.2, 138.9, 132.6, 121.6, 119.5, 113.3, 74.9, 74 (d, JC-P = 7.3 Hz), 72.3, 68.8, 49.3, 
23.2, 20.8; 31P NMR (121 MHz, D2O) δ ppm 2.5; HRMS (ESI-) calculated for 
C18H21N3O9P (M-H)- m/z = 454.1015, found 454.1016. 
FMN binding assays.  Binding assay solutions contained apo wild type and 
monomeric spIDI-2, 1 % glycerol and substrate in 100 mM HEPES, pH 7.0. Mixtures 
were incubated for 10 min at 37 °C, then transferred to a 30 kDa MWCO centrifugal 
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filter and incubated an additional 5 min at 37 °C. The samples were centrifuged at 
different speeds to allow < 10 % of the assay volume to pass through the membrane. UV-
vis absorption spectra were collected for the filtrates. Spectra were collected until there 
was no increase in absorption at 450 nm for 3 consecutive measurements, and then 
averaged. All binding assay experiments were replicated 3 times. 
15N-1H HMBC protein-FMN NMR studies. NMR spectra obtained at 25 oC on a 
600 MHz spectrometer equipped with a cold probe.  15N-1H HMBC NMR spectra were 
collected for samples containing 300 µM wild type protein in 50 mM phosphate buffer 
pH 7.0 containing 240 µM FMN, 10% D2O in 700 µL volume. For the monomer, 300 µM 
protein in 50 mM phosphate buffer pH 7.0 containing 300 and 600 µM FMN, 10% D2O 
in 700 µL volume. Monomeric spIDI-2 NMR sample additionally contained 150 mM 
NaCl and 2 mM DTT. For the free FMN NMR, 240 µM FMN in 50 mM phosphate 
buffer pH 7.0 containing 10% D2O in 700 µL volume. 
 
 
Results and Discussion 
Our synthetic approach consists of the five step chemo-enzymatic route shown in 
Scheme 3.1, where four chemical steps are followed by a final enzyme-catalyzed 
phosphorylation of riboflavin 7. The overall sequence is based on literature precedents 
for each chemical step through the Tishler condensation to give 7, although the reaction 
conditions, work-up procedures and purification steps were substantially modified. We 
then used riboflavin kinase (RFK), which is regiospecific for the 5’-OH, to convert 7 to 
5’-FMN.160 In contrast, chemical phosphorylation of 7 is not regiospecific, giving a 
mixture of monophosphates, bisphosphates, and cyclic phosphates that is difficult to 
	   
87 
separate.161 This approach not practical when using expensive 15N and 13C-enriched 
substrates. 
The substrates for the Tishler condensation, barbituric acid 3 and amino o-
azoribitol derivative 6, were synthesized from materials that permit us to introduce labels 
at N1/N3, N5, N10, C4a, and C2/C4 of 7 by the route outlined in Scheme 3.11. We 
reproduced the reported good yields for synthesis of 3 from urea 1 and diethyl malonate 
2155 and the reductive amination of 3,4-dimethyl aniline 4 with D-ribose and sodium 
cyanoborohydride (NaCNBH3) to give N-ribityl 3,4-dimethyl aniline 5.156 The low yield 
(~20%) for conversion of 5 to 6 with NaNO2/HOAc/NaOH was improved considerably 
(95%) by adapting the procedure reported by Folkers and coworkers for synthesis of L-
lyxoflavin where HOAc/NaOH was replaced by NaOAc.157 
Purification of 7 following condensation of 6 with barbituric acid 3 proved to be 
difficult. We were not able to obtain good yields following the lengthy purification 
protocol, which includes several washes with water and MeOH, extractions with ether, 
and recrystallization with superoxol,157 which are necessary to provide pure 7 for a 
chemical phosphorylation.  We verified that phosphorylation of 7 with POCl3 gave a 
mixture of regioisomers that are hard to separate by HPLC.161 Instead, the reaction 
mixture containing 7 from the condensation of 3 and 6 was washed with water and cold 
methanol and used directly for the RFK-catalyzed phosphorylation, thereby preventing a 
substantial loss of material during repeated washings, extractions, and recrystallization. 
Incubation of crude 7 with ATP and RFK gave 5’-FMN in > 95% yield.   
The reactions shown in Scheme 3.2 were used to synthesize 7 with 15N at 
positions N1/N3 and N5, 13C at C4a, and 13C/15N at C4a/N5. [N1,N3-15N2]- and [C4a-
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13C]7 were synthesized from labeled barbituric acid as outlined in Scheme 3.1. [1,3-
15N2]- and [5-13C]Barbituric acids were prepared from [1,3-15N2]urea and diethyl [3-
13C]malonate, respectively162,163. Condensation of the labeled barbiturates with azoribitol 
6 gave the corresponding labeled riboflavins. [N5-15N]- and [C4a-13C, C5-15N]Riboflavin 
were prepared as shown in Scheme 3.3. [N5-15N]7 was prepared by treatment of ribityl 
amine 5 with Na15NO2/HCl followed by coupling of the labeled diazonium intermediate 
with aniline to give 15N-azoribitol 6. Condensation of labeled 6 with barbituric acid gave 
[5-15N]7 and with [5-13C]barbituric acid gave [C4a-13C, C5-15N]7. 
The overall yields of labeled riboflavins for the three steps from barbituric acid 
ranged from 29-43%. The poorest yields were for the final conversion of 6 to 7 (43-64%).  
We experienced additional losses at this step during attempts to purify 7 from the reaction 
mixture. Riboflavin is poorly soluble in water and common organic solvents, which 
severely limits its purification by chromatography, and we encountered substantial losses 
during recrystallization. As a result, homo sapiens riboflavin kinase (hsRFK) was used to 
phosphorylate unpurified 7 with ATP.  The labeled riboflavins were dissolved in a 
minimal volume of DMSO and added to hsRFK to give a reaction buffer that contained 
~1% DMSO. The enzyme-catalyzed phosphorylation was regioselective for synthesis of 
5-FMN. Impurities in the labeled riboflavin samples did not interfere with the reaction, 
giving excellent conversions of 7 to FMN, which was purified by HPLC (Scheme 3.4, 
Table 3.1). The same procedure was used to phosphorylate 5-deazariboflavin 8 to give 5-




Dissociation constants.  The dissociation constants (KD) for apo wild type spIDI-2 
and monomeric spIDI-2 for FMN were determined with an ultrafiltration assay and data 
were fit to the Hill Equation shown below. The data and best-fit lines are shown in Figure 
3.4. KDFMN = 3.07 ± 0.43 µM and n = 1.9 ± 0.18 for wild type tetramer, KDFMN = 98 ± 3.5 
µM and n = 2.72 ± 0.21 for monomeric spIDI-2 where n represents the number of 
FMNH2 molecules bound per molecule of apo-spIDI-2. There are no reports suggesting 
that IDI-2 binds more than one molecule of FMN, however, these results yielded an n 
value significantly greater than 1, with data fitting n for FMN ~ 2. Dissociation constants 
were determined in order to carry out NMR studies with unlabeled wild type and 
monomeric spIDI-2 by reconstituting the apo enzymes with 15N- and 13C-labeled FMN 
isotopologues that were previously synthesized and discussed earlier in this chapter. 
Identifying dissociation constants for FMN in both proteins will help to accurately 
reconstitute both enzymes with FMN in the completely enzyme-bound form to detect its 
NMR signals. The NMR studies are aimed to gain insights in to the structure of enzyme 
bound flavin zwitter-ion as well as the pKa of the labeled centers in FMN as outlined in 
the following section.  
15N-1H HMBC NMR studies.  We performed HMBC NMR experiments in an 
attempt to study the reduced flavin zwitter-ionic structure in the active site of the enzyme 
as shown in Figure 1.14 (Chapter 1). By utilizing the [5-15N] FMN and incorporating into 
both wild-type and monomeric apo IDI-2, the goal is to observe the [5-15N] multiplicity 
of FMN in the oxidized, reduced and zwitter-ionic states including the catalytically active 
complex IDI-2FMNredIPP/DMAPP in which we predict FMNred exists in zwitter-ionic 
tautomer. Additionally, we aimed to study the change in 15N chemical shift (δ) as a 
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function of pH to identify the pKa of N(5) in the active site of the enzyme.  This similar 
pH-pKa titration study could be extended to study the pKa of the other labeled centers in 
the FMN isotopologues that we synthesized. Towards these goals, we have collected the 
15N-1H HMBC spectrum of [5-15N] FMN and observed the 3J 15N-1H correlation of C(6)-
H and N(5) (Figure 3.5 and 3.6A) in the free form but when the flavin binds either the 
wild type spIDI-2 tetramer or monomer, the 3J 15N-1H HMBC signal disappeared 
indicating an exchange mechanism and the corresponding HMBC signal could not be 
detected (Figure 3.6B and 3.6C).  
Similarly, 1H-NMR study utilizing unlabeled FMN by monitoring the C7 and C8 
methyl groups of FMN indicated that at lower concentrations of FMN (up to 1:4 
Protein:FMN for wild type and 1:8 for monomer) 1H signals were absent but the 1H 
signals appeared at higher FMN concentrations indicating that the observed 1H signals 
are indicative of free unbound FMN but not enzyme bound FMN (Figure 3.7).  
Therefore, both the 15N-1H HMBC and 1H-NMR studies revealed that NMR signals for 
the FMN in the enzyme-bound state could not be observed by NMR due to rapid 
exchange mechanisms between bound and unbound forms.  
As an alternative strategy, we are utilizing Raman spectroscopy to study the 
proposed enzyme-bound flavin zwitter-ionic structure in IDI-2. Raman spectroscopy is an 
important tool to study flavins and flavoproteins since the Raman bands of flavins are 
sensitive to redox, protonation states of flavin isoalloxazine ring, hydrogen bonding, 
steric interactions, and planarity of the isoalloxazine ring.165,166 Isotopically labeled 
flavins have been applied to study the flavins in oxidized and semiquinone states along 
with computational approaches such as DFT calculations.167-170 Therefore, we are 
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currently utilizing resonance Raman spectroscopy to study the differences of Raman 
bands of FMN in oxidized, reduced, and zwitter-ionic states in the active site of IDI-2.  
In summary, we describe an efficient five-step synthesis of 13C and 15N FMN 
isotopologues labeled at positions C1, C3, C4a, and N5 of pyrazine and pyrimidine rings 
in the isoalloxazine nucleus in yields ranging from 29% to 43% from commercially 
available labeled precursors (Figure 3.8). Our synthesis can be also adapted to label other 
carbon, nitrogen, hydrogen, and oxygen atoms in the isoalloxazine ring system by 
starting with the suitable 15N or 13C enriched precursors. Although the final step involves 
a RFK-catalyzed phosphorylation requiring ATP to synthesize the labeled riboflavins to 
the corresponding FMN derivatives, an expression plasmid for RFK is available and ATP 
regeneration protocols can be used for larger scale syntheses.171 
Furthermore, we have measured the dissociation constants (Kd) for FMN in both 
wild type tetrameric and monomeric spIDI-2 and performed 15N-1H HMBC and 1H-NMR 
studies by reconstituting the wild type and monomeric apo spIDI-2 with [5-15N]FMN and 
unlabeled FMN. These studies were performed to identify the pKa of N(5) and other 
nuclei such as C(4a), N(1) in FMN as well as the multiplicity of N(5) NMR signal in IDI-
2FMNred, IDI-2FMNredIPP/DMAPP complexes to gain insights about the protonation 
states and the pKa’s of the labeled positions in FMN responsible for IDI-2 catalysis. We 
found that NMR is not a suitable technique to study the enzyme-bound FMN pKa’s and 
the zwitter-ionic structure since the FMN signals could not be detected due to exchange 
mechanism between bound and unbound states. Therefore, we are currently utilizing 
resonance Raman spectroscopy to identify the differences in the Raman spectra of flavin 
in oxidized, reduced and zwitter-ionic states along with computational approaches. The 
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15N- and 13C-FMN isotopologues will be utilized to collect the Raman spectra of FMN-




Figure 3.1. Structures of riboflavin, FMN, and FAD. 
 
 









































































































































































































































Scheme 3.3. Synthesis of [4a-13C]7 and [1,3-15N2]7. 
 



















































































N = 15N and C (deaza, 8)
C = 13C
N = 15N 97 % - quant
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15N(5)-Riboflavin 7a (10 mg) 75 15N(5)-FMN (8.94 mg) 98 
13C(4a)-Riboflavin 7b (10 mg) 80 13C(4a)-FMN (9.38 mg) 97 
15N(5)13C(4a)-Riboflavin 7c (10 mg) 59 15N(5)13C(4a)-FMN (7.19 mg) >98 
15N(1)15N(3)-Riboflavin 7d (10 mg) 86 15N(1)15N(3)-FMN (10.66 mg) >98 
5-deazaRiboflavin 7e (12 mg) 88 5-deaza-FMN (12.52 mg) 98 
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[E*FMN]E!"!#$ = 𝑛1+ 𝐾!FMN!"## ! =
𝑦!"#1+ 𝐾!FMN!"## ! 
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Figure 3.6. 15N-1H HMBC of A) [5-15N]FMN B) [5-15N]FMN + monomeric spIDI-2 C) 







































 	  	  
 
Figure 3.7. 1H-NMR of increasing concentrations of FMN at constant concentration of 
protein A) FMN + wild type spIDI-2 B) FMN + monomeric spIDI-2 (P indicates protein). 








































































































































Several lines of evidence, including active-site-directed inhibition, site-directed 
mutagenesis, and studies with substrate analogues and transition state inhibitors, suggest 
that IDI-1 and IDI-2 catalyze isomerization via a protonation-deprotonation 
mechanism.50,52,82,85,88,90-92,98,104b,172 IDI-1 and IDI-2 differ not only by their amino acid 
sequences, their tertiary and quaternary structures, and the catalytic residues in their 
active sites, but also by their facial selectivity during protonation-deprotonation. IDI-1 
catalyzes an antarafacial isomerization57 during which the active site glutamate acts as an 
acid by protonating the si-face of the double bond and cysteine acts as a base to 
stereospecifically abstract the pro-R proton from C2. In contrast, IDI-2 catalyzes a 
suprafacial isomerization91 where the flavin cofactor acts as an acid-base catalyst to 
protonate the re- face of the double bond of IPP and abstract the pro-R proton from C2 
(Scheme 4.1).76 The isomerization of IPP to DMAPP catalyzed by IDI-1 or IDI-2 could 
proceed via tertiary (3o) carbocationic intermediate or a structurally related transition 
state (Figure 4.1). Two groups (Abeles and Poulter) independently obtained support for 
the carbocationic intermediate for the reaction catalyze by IDI-1 in their studies with
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IPP analogs for IDI-1, including a positively charged ammonium mimic of the putative 
carbocation (NIPP). 58,59,80,89 Formation of the carbocationic intermediate requires a step-
wise mechanism. Poulter and coworkers obtained additional support for the carbocationic 
intermediate for IDI-2 using a thiomethyl analog of IPP and with other electrophilic IPP 
analogs. Collectively, the studies suggested that both IDI-1 and IDI-2 behave similarly by 
generating a 3o carbocationic intermediate via a step-wise mechanism for IPP/DMAPP 
isomerization. Richard and coworkers suggested a concerted mechanism from model 
studies based on linear free energy (LFE) correlations of the nonenzymatic acid catalyzed 
isomerization of 4-(4-methoxyphenyl)-2-methyl-1-butene to 4-(4-methoxyphenyl)-2-
methyl-2-butene in mixtures of trifluoroethanol (TFE)/water (Figure 4.2A).68 The results 
suggest that the kinetic barrier for deprotonation of the tertiary carbocation is 
significantly less than that for protonation of enolates by water. Due to the low-energy 
kinetic barrier for deprotonation, they proposed a concerted mechanism. Comparison of a 
carbocationic intermediate to an ‘‘enolate’’ intermediate in enzymatic reactions suggests 
that “enolate” intermediates have ‘‘low barrier’’ hydrogen bonds to hydrogen bond 
donors in the active site residues of the enzymes. However, this type of hydrogen 
bonding, which requires that the pKa’s of the hydrogen bond donor and acceptor be 
closely matched, does not seem plausible for an enzyme-bound 3o carbocationic 
intermediate where its estimated pKa of ~ -12 is much more negative than those of 
hydrogen bond donors in amino acid side chains.   
Richard and coworkers also undertook model studies with 1-(4-methoxyphenyl)-
3-methyl-3-butyl-X derivatives in aqueous solvents both in the presence and absence of 
the strong nucleophile azide (N3-)  (Figure 4.2B).69 Addition of azide did not affect the 
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yields of the resulting alkene products which further supports a concerted mechanism that 
operates via a carbocationic-like transition state.  
Although these reports favor a concerted mechanism, they are based on 
nonenzymatic model reactions in aqueous solvents rather than the active sites of IDI-1 
and IDI-2. Thus, we undertook a different approach by studying deuterium incorporation 
into IPP and DMAPP during isomerizations catalyze by IDI-1 and IDI-2 reactions in 
D2O. We now present compelling evidence that the protonation-deprotonation steps in 





Reagents and chemicals.  Cell culture growth media, salts, and chemicals were 
purchased from Fisher Scientific, B&D, and Sigma-Aldrich. HRMS-ESI data were 
recorded on LC-TOF and LTQ-FTMS mass spectrometers. Samples from incubation of 
IPP with IDI-1 and IDI-2 were analyzed by RP-HPLC on a Phenyl column (Waters, 19 × 
100 mm) that had been equilibrated with H2O. Products were eluted with a H2O-ACN 
gradient (0-100% H2O/ACN) with a run time of 15 min at a flow rate of 1 mL/min. 
Under these conditions, the retention time (rt) for dimethylallyltryptophan (DMAT) was 
~ 14 min. IDI-2 assays were performed under oxygen free conditions in an anaerobic 
chamber (Coy). The purity of the proteins was determined by sodium dodecyl sulphate-
polyacrylamide gel electrophoresis (SDS-PAGE). Protein concentration was determined 




IPP and DMAPP synthesis. Isopentenyl diphosphate and dimethylallyl 
diphosphate was synthesized as per the procedure described by Davisson et. al.173 
E. coli IDI-1 overexpression and purification. Plasmid (pAPHIII22) encoding the 
gene for E. Coli IDI-1 and the E. coli expression strain JM101 was used as reported174 
with the following modifications. The cell cultures were grown in Luria broth, containing 
100 µg/mL of ampicillin, at 37 °C, 230 rpm until OD600 ~ 0.6. Overexpression of the 
protein was induced by the addition of nalidixic acid (final concentration of 0.2 mM) as 
described previously. The cells were suspended in lysis buffer (50 mM sodium 
phosphate, pH 8.0, containing 300 mM NaCl and 10 mM imidazole) with the addition of 
lysozyme (10 mg), one protease inhibitor tablet (Roche), and DNase I (2 mg) on ice for 
30 min followed by sonication (6 X 30 s cycles, 1 min cooling intervals on ice). The cell 
lysate was centrifuged (12000 rpm, 25 min, 4 °C) and the resulting supernatant was 
mixed with 10 mL of Ni-NTA Agarose resin (Qiagen) and loaded on to a column. Flow-
through was collected, and the protein-bound Ni-NTA agarose resin was washed with 50 
mM sodium phosphate, pH 8.0, containing 300 mM NaCl and 20 mM imidazole. Protein 
was eluted with 50 mM sodium phosphate, pH 8.0, containing 300 mM NaCl, and 250 
mM imidazole and the fractions containing IDI-1 were pooled, concentrated with a 10 
kDa MWCO filter (Centriprep, Millipore) and dialyzed against 10 mM Tris buffer, pH 
8.0. The protein was then lyophilized and suspended in 99.9% D2O and concentrated with 
a 10 kDa MWCO filter. This process was repeated 4-5 times before the protein was 
suspended in 10 mM Tris, pD 8.0 D2O buffer and stored at -80 oC until use.  
Streptococcus pneumoniae IDI-2 overexpression and purification. spIDI-2 
overexpression and purification was performed as described previously.98 After 
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purification and dialysis, the protein was lyophilized and suspended in 99.9% D2O buffer 
and washed 4-5 times with 10 mM Tris, pD 8.0 in a 10 kDa MWCO filter and stored at -
80 oC until use.  
Claviceps purpurea 4-DMATS overexpression and purification. cp4-DMATS 
overexpression and purification was performed as described previously.175 After 
purification and dialysis, the protein was lyophilized and suspended in 99.9% D2O buffer 
and washed 4-5 times with 10 mM Tris, pD 8.0 in a 10 kDa MWCO filter and stored at -
80 oC until use. 
IDI-1, 4-DMATS coupled assay in D2O buffer.  All the reagents were thoroughly 
exchanged with D2O by repeated lyophilization. 4-DMATS (40 µM) was incubated with 
10 mM L-Trp, 2 mM IPP, 0.1 mg/mL BSA, 10 mM MgCl2, 1 mM DTT in a total volume 
of 2.5 mL (pH 7.8). The reaction was initiated by addition of (20 µL) 1 µM IDI-1. 
Samples (260 µL) were collected at 0.5h, 1h, 1.5h, 2.5h, 4h, 6h, 9h, and 12.5h. The 
enzyme was removed with a 10 kDa MWCO filter and the resulting filtrate was 
lyophilized, and fractionated by RP-HPLC (phenyl column, 0-100% H2O-ACN gradient) 
into samples containing IPP and DMAT. IPP, which eluted in the void volume under 
these conditions, was further purified by anion-exchange chromatography as described 
below. The samples of IPP and DMAT were analyzed by ESI-MS to identify the 
deuterium content in both compounds. 
Anion-exchange chromatography.  The void volume fraction from the reversed 
phase separation were lyophilized, dissolved in 500 µL of water and loaded on to an 
anion-exchange column (Strata-Z-AW 33 µm, Phenomenex) that had been washed with 
methanol equilibrated with water. IPP was eluted ammonium hydroxide (NH4OH) in 
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MeOH (5:95 v/v). Samples were lyophilized and analyzed by mass spectrometry. 
IDI-2, 4-DMATS coupled assay in D2O buffer.  The same procedure outlined 
above was repeated with the following modifications. 10 nM IDI-2 was used and the time 
point aliquots were collected at 0h, 1h, 4h, 6h, 8h, 12h, and 24h and the enzyme was 
separated with a 30 kDa MWCO filter. 
Control assays with DMAPP.  Same procedure as above except 2 mM DMAPP 




Stepwise versus concerted mechanism of IDI: Design of the experiment.  To 
distinguish between step-wise and concerted mechanisms for isomerization of IPP to 
DMAPP, we designed a time-course experiment where isomerization of IPP to DMAPP 
by IDI was coupled to alkylation of tryptophan by DMAPP with dimethylallyltryptophan 
(4-DMAT) synthase under conditions where newly synthesized DMAPP that had been 
released from IDI was removed from the system and could not return to IPP. The coupled 
assay was run in D2O where a deuterium was added to C4 of IPP during the isomerization 
(Scheme 4.2).  
IPP was incubated with S. pneumoniae IDI-2 or E. Coli IDI-1 and Claviceps 
purpurea 4-DMAT synthase. The [Trp] was 5-fold greater that the [IPP] and the specific 
activity of DMAT synthase activity was 40 times greater than that of IDI-1 and 1000 
times than IDI-2. All of the buffer reagents, substrates and proteins were thoroughly 
exchanged with deuterium by repeated lyophilization and the reactions were initiated by 
the addition of IDI. As the reaction proceeded, samples were removed, the enzymes were 
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immediately separated from small molecules by ultrafiltration. The reactants and 
substrates were purified by HPLC and analyzed by positive ion mass spectrometry (MS). 
For both IDI isozymes, the final product, 4-DMAT, contained one, two, and ultimately 
three deuterium atoms from DMAPP during the course of the incubation (Figures 4.3 and 
4.4). The 13C isotope peaks in unlabeled DMAT for M+1 (~20 % of M) and M+2 (2 % of 
M) agreed with theoretical values. The intensities of the M+1 and M+2 peaks were 
greater that the 13C background and there was no background at M+3, reflecting 
incorporation of additional deuterium atoms into the DMAPP during isomerization. In 
control experiments for both isoforms where unlabeled DMAPP replaced IPP, no 
deuterium was incorporated into DMAT, indicating that DMAPP was efficiently trapped 
without isomerizing to IPP even under conditions were the initial concentration of 
DMAPP was substantially higher than DMAPP was formed from IPP (Figures 4.5 and 
4.6). In the control assay with DMAPP, the observed M+1 peak was ~20% of M and 
M+2 is of ~2% of M and are similar to the unlabeled DMAT standard. Time courses for 
incorporation of IPP into DMAT via DMAPP for IDI-1 and IDI-2 are shown in the 
Figure 4.7. The ratios of d1, d2, and d3 DMAT at each point in the time course for the 
isozymes are given in Tables 4.1 – 4.8, respectively. 
The relative ratios of d2, d3-DMAPP (or d2, d3-DMAT) in IDI-2 catalyzed 
reactions are much higher than the IDI-1 catalyzed reactions indicating more deuterium 
incorporation in to the product DMAPP and eventually into DMAT (Table 4.1 – 4.8). 
Lower deuterium incorporation in IDI-1 conversion could be due to lower rates of 
enzymatic release of the product DMAPP as reported by Richard and coworkers. 
IPP was also isolated and analyzed by negative ion mass spectrometry at each of 
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the above time points for IDI-1 and IDI-2. Since IPP elutes in the void volume of the 
phenyl column used in the LCMS analysis of DMAT (Figures 4.8 – 4.10), the void 
volumes were collected, lyophilized, and analyzed by LCMS on a phenyl column. Along 
with unlabeled IPP, the d1, d2, d3 isotopomers of IPP were detected at each point in the 
time course (Figures 4.8 and 4.9). The relative amounts of d1, d2, d3-IPP increased as the 
reactions proceeded (Tables 4.9 – 4.15). The presence of deuterium in IPP under 
conditions where free DMAPP is trapped by DMAT synthase unambiguously 
demonstrates that a portion of newly bound IPP is protonated (deuterated) and ultimately 
released as IPP before being released as DMAPP.  
The isomerization reactions of IDI-1 and IDI-2 are highly stereoselective for 
protonation/deprotonation at C2 and C4 of IPP and DMAPP.65,78 The d1 and d2 
isotopomers of IPP can be explained by incorporation of deuterium as C4. However, d3-
IPP, especially at the relatively high percentages found in the time course experiments, is 
predominantly [C2-2H2, C4-2H]IPP and the d2-isotopomer is a mixture of [C2-2H2]IPP 




The design of the deuterium incorporation experiment prevents DMAPP newly 
released from the active site of IDI from being isomerized back to IPP. Inspection of the 
reactions involved in transformation of IPP to DMAPP shown in Scheme 4.3 shows a 
potential difference in the pattern of deuterium incorporation into unbound IPP during the 




In a concerted mechanism, enzyme bound unlabeled IPP is converted into enzyme 
bound d1-DMAPP labeled at C4, which can be released and trapped as DMAT or 
isomerized to IPP. If the proton removed from C2 during isomerization protonates C2 in 
the reverse reaction, d1-IPP will be formed. However, if the proton exchanges with 
deuterium before protonation, d2-IPP will be generated. In a stepwise mechanism, the 
initially formed species is the tertiary carbocation labeled at C4. This species can 
partition to DMAPP by elimination of a proton from C2 or to IPP by elimination of a 
proton/deuterium from C4. The lifetime of the tertiary carbocation (estimated at ~10 
ns)176 is sufficiently long for the deuterium atom at C4 to scramble with the two hydrogen 
atoms in the newly formed methyl group by rotation about the C3-C4 bond. The primary 
isotope effect kH/kD ~ 6177 for removing hydrogen versus deuterium from C4 will result in 
a ~12-fold selectivity for removal of one of the two C4 hydrogens over the deuterium. In 
this case, d1-IPP is formed directly from the carbocationic intermediate. In addition, 
enzyme bound d1-DMAPP can revert to IPP to generate d1- or d2-IPP as described for the 
concerted mechanism. These possibilities are illustrated in Scheme 4.3.  
IPP, deuterated IPP, and DMAPP shown above could be formed from either the 
concerted mechanism (Scheme 4.3A) or the step-wise mechanism through a 3o 
carbocationic intermediate (Scheme 4.3B) generated upon “D+” addition to IPP as 
outlined above. There is a possibility that the trace amounts of “H+” leak from the C2 or 
C4 hydrogens in IPP/DMAPP during the isomerization to the active site residues in IDI-1 
and IDI-2 in the enzyme assays, and therefore increases unlabeled or labeled IPP and 
DMAPP peak ratios in the time-course of the reactions analyzed by mass spectrometry. 
Poulter and coworkers reported that Saccharomyces cerevisiae IDI-1 catalyzes the 
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IPP/DMAPP isomerization in a less stereoselective manner.65 Upon extended periods of 
incubation of IDI-1 isomerization of IPP in D2O all the hydrogens in IPP are exchanged 
with deuterium except those at C1. Two percent of the time IPP undergoes deuteration 
from solvent D2O at Z-methyl group (C5 methyl hydrogens in IPP) and one half percent 
of the time it undergoes deuteration at pro-R C2-hydrogen of IPP. Similar behavior was 
not observed for E. Coli IDI-1 even upon extended periods of incubation of IPP. The rate 
constants in Scheme 4.4 accounts for a statistical factor associated with the number of 
hydrogens and deuteriums that are present at C4 position in the 3o carbocationic 
intermediate.  
Unlike IDI-1, the mechanism of IDI-2 catalyzed IPP and DMAPP is highly 
stereoselective. Barkley et. al. observed that only the C-4 methylene hydrogens and the 
pro-R C2-hydrogen were exchanged when IDI-2 reaction catalyzed IPP isomerization 
was incubated in D2O.78 Even upon extended incubations of IDI-2 in D2O, there was no 
deuterium at any other locations other than C2 and C4 of IPP and DMAPP. Similar to 
IDI-1, IDI-2 also generated d1, d2, d3-IPP, and d1, d2, d3-DMAPP although the ratios of 
d2,d3-DMAPP in IDI-2 are much higher than IDI-1.  
Identification of d1, d2, and d3-DMAPP (which are converted into d1, d2, d3-
DMAT using a 4-DMATS coupling enzyme) along with IPP, d1, d2, and d3-IPP in the 
reaction time-courses for both IDI-1 and IDI-2 strongly suggests that both enzymes 
catalyze the reaction via a step-wise mechanism shown in Scheme 4.3B through the 
formation of 3o carbocationic intermediate. As predicted for the step-wise mechanism, all 
the hydrogens on the C4 of IPP and DMAPP are completely exchanged with deuterium. 
Moreover, IDI-1 and IDI-2 differ significantly in terms of the d1:d2-IPP ratios in the time-
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course analysis of IPP isomerization that we developed (Table 4.16). At the early stages 
of the IDI-1 reaction (0.5 hours) the d1:d2-IPP ratio was found to be ~ 0.48:52. The d1 and 
d2-IPP ratios will be governed by the 3o carbocation that is created by the addition of 
“D+” to C4 of IPP [C4-2H]IPP that has preferential selectivity towards eliminating a 
proton than a deuterium on CH2D methyl group of C4 and the KIE estimated for this 
process to be < 5. On the other hand, the d1:d2-IPP ratio was found to be ~ 0.12:0.88 for 
the IDI-2 reaction at 1 h and has the estimated KIE of ~ 5 for the similar 3o carbocation. 
The d1:d2-IPP ratios were almost identical (1:1) in IDI-1 and significantly different (1:8) 
in IDI-2 at the early stages of the reaction. d1-IPP is unlikely to be formed by a concerted 
process (Scheme 4.3A) since it requires the deuterium on C4 to be eliminated when the 
addition of “D+” to d1-DMAPP that generates d1-IPP. The significant amounts of d1-IPP 
at the early stages of IDI-1 and IDI-2 reactions indicate a step-wise mechanism for both 
enzymes. Additionally, if the mechanism is concerted, the d1:d2-IPP ratios for both IDI-1 
and IDI-2 should be relatively constant during the time-course of the assays although the 
individual concentrations of d1:d2-IPP differ. We did not observe constant ratios of d1:d2-
IPP in our time-course analysis of IPP isomerization by IDI-1 and IDI-2 further 
suggesting concerted mechanism is not likely.  
Richard and coworkers undertook NMR studies of IDI-1 catalyzed IPP 
isomerization in D2O and found that the product after the first catalytic cycle (d1-
DMAPP) is not released but rather undergoes additional rounds of catalysis to generate 
d1-IPP and d2-DMAPP before being released from the active site of the enzyme.70 
Support for this observation came from that both d1-IPP (the product after two catalytic 
cycles) and d1-DMAPP (the product after first catalytic cycle) forms with the same 
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reaction velocity and the ratios of these products are constant at the early stages of the 
reaction. This result indicates that the release of d1-DMAPP is slower than its conversion 
to d1-IPP and based on these results they propose that the product release is the rate-
determining step of the IDI-1 catalysis. We also observed similar trend that the product 
after first catalytic cycle (d1-DMAPP) undergoes multiple catalytic turnovers to produce 
d2-DMAPP and d3-DMAPP simultaneously before finally being released from the 
enzyme for both IDI-1 and IDI-2. 
Altogether, the data presented above strongly supports the step-wise mechanism 
going through a 3o carbocationic intermediate of the IPP and DMAPP isomerization 




In summary, we obtained the evidence for the tertiary (3o) carbocationic 
intermediate for the IPP and DMAPP isomerization catalyzed by both IDI-1 and IDI-2 
and the reaction proceed through step-wise mechanism. Both enzymes IDI-1 and IDI-2 
are identical in terms of number of deuteriums incorporation into the substrate and 
product except that the relative deuterium content of d2, d3-IPP and DMAPP is higher for 
IDI-2. We did not observe reverse reaction of DMAPP isomerization into IPP in our 
control assays with DMAPP at the mentioned reaction conditions. IDI-1 from 
Saccharomyces cerevisiae reported to incorporate solvent deuterium into all the carbons 
in IPP except C1,65 we did not see similar trend with E. coli IDI-1 indicating E. coli IDI-1 
is much more stereoselective in catalysis. The rate constants for the formation of d1, d2, d3-
IPP and DMAPP from unlabeled IPP (Schemes 4.3B) as shown for step-wise mechanism 
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could be obtained by fitting the above experimental data in Tables 4.1 – 4.15 to the 
kinetic modeling software (KinTek) and this study is currently is in progress. Taken 
together, IDI preferentially catalyze IPP/DMAPP isomerization through the generation of 
a 3o carbocationic intermediate. The preference for the carbocation probably derives from 
the large net stabilization energy gained through electrostatic and other noncovalent 


















Scheme 4.1. IPP/DMAPP isomerization catalyzed by A) IDI-1 in an antarafacial B) IDI-















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 4.10. HPLC chromatogram of retention times (rt) of IPP (Vo), L-Trp and DMAT 
at λ210 on a RP-Phenyl column. Unreacted L-Trp peak is also shown. 
 
 









	    296.1 (d1) 297.2 (d2) 298.2 (d3) 
0.5  3 0.75 0.21 0.04 
1.5 18 0.8 0.18 0.02 
2.5  33 0.79 0.19 0.02 
4  81 0.74 0.22 0.04 
6 79 0.73 0.23 0.04 













	    296.1 (d1) 297.2 (d2) 298.2 (d3) 
0.5  9 0.74 0.22 0.04 
1 18 0.78 0.2 0.03 
1.5  33 0.75 0.21 0.04 
2.5  49 0.76 0.21 0.03 
4 66 0.74 0.22 0.04 
6 68 0.7 0.25 0.05 














	    296.1 (d1) 297.2 (d2) 298.2 (d3) 
0.5  5 0.75 0.21 0.04 
1 11 0.77 0.2 0.03 
1.5  21 0.78 0.2 0.02 
2.5  38 0.77 0.2 0.03 
4 61 0.75 0.22 0.03 
6 79 0.68 0.27 0.05 
9 96 0.66 0.27 0.07 









(%)* ± S. D 




	    296.1 (d1)  297.2 (d2)  298.2 (d3)  
0.5  6 ± 3 0.75 ± 0.01 0.21 ± 0.01 0.04 ± 0 
1 15 ± 4 0.77 ± 0 0.2 ± 0 0.03 ± 0 
1.5  24 ± 8 0.78 ± 0.02 0.19 ± 0.01 0.03 ± 0.01 
2.5  40 ± 8 0.77 ± 0.01 0.2 ± 0.01 0.03 ± 0.01 
4 69 ± 10 0.74 ± 0.01 0.22 ± 0 0.04 ± 0.01 
6 75 ± 6 0.71 ± 0.03 0.25 ± 0.02 0.04 ± 0.01 
9 96 ± 0 0.66 ± 0 0.27 ± 0 0.07 ± 0 
12.5 96 ± 3 0.65 ± 0.02 0.27 ± 0.01 0.08 ± 0.02 
Assay conditions: 2 mM IPP, 12 mM L-Trp, 0.1 mg/mL BSA, 10 mM MgCl2, 1 µM 
IDI-1, 40 µM 4-DMATS pD 7.8, 30 oC, reaction volume 2.5 mL. *Conversions were 
quantified by RP-HPLC on a phenyl column. 9h is not average. S.D Standard Deviation. 
 









	    296.1 (d1) 297.2 (d2) 298.2 (d3) 
1  6 0.68 0.24 0.08 
4  25 0.67 0.25 0.08 
8  51 0.63 0.28 0.09 
12 70 0.59 0.29 0.12 















	    296.1 (d1) 297.2 (d2) 298.2 (d3) 
1  3 0.66 0.28 0.06 
4  16 0.66 0.26 0.08 
6  26 0.65 0.27 0.08 
8 36 0.63 0.27 0.1 
12  53 0.6 0.29 0.1 
















	    296.1 (d1) 297.2 (d2) 298.2 (d3) 
1  7 0.69 0.25 0.06 
4  27 0.67 0.26 0.07 
6  37 0.65 0.27 0.08 
6 42 0.65 0.27 0.08 
8  55 0.63 0.27 0.1 
12 76 0.59 0.29 0.12 
12 77 0.59 0.29 0.12 










(%)* ± S. D  




	    296.1 (d1)  297.2 (d2)  298.2 (d3)  
1  5 ± 2 0.68 ± 0.02 0.26 ± 0.02 0.06 ± 0.02 
4 22 ± 6 0.67 ± 0 0.26 ± 0 0.07 ± 0 
6  35 ±8 0.65 ± 0 0.27 ± 0 0.08 ± 0 
8  47 ± 10 0.63 ± 0 0.28 ± 0 0.09 ± 0 
12 69 ± 11 0.59 ± 0.01 0.29 ± 0 0.12 ± 0 
24 100 ± 0 0.5 ± 0.05 0.31 ± 0.01 0.19 ± 0.05 
 
Assay conditions: 2 mM IPP, 10 mM L-Trp, 0.5 mM FMN, 5 mM Na2S2O4, 0.1 mg/mL 
BSA, 10 mM MgCl2, 10 nM spIDI-2, 10 µM 4-DMATS pD 7.8, 30 oC, reaction volume 















	   	  
	    245 (d0) 246 (d1) 247 (d2) 248 (d3) 
0.5  9 0.91 0.04 (0.44) 0.04 (0.44) 0.01 (0.12) 
1  18 0.9 0.03 (0.26) 0.06 (0.56) 0.01 (0.18) 
1.5  33 0.85 0.05 (0.32) 0.08 (0.52) 0.02 (0.16) 
2.5  49 0.8 0.07 (0.36) 0.11 (0.53) 0.02 (0.11) 
4 66 0.65 0.1 (0.3) 0.2 (0.56) 0.05 (0.14) 
6  68 0.41 0.14 (0.25) 0.31 (0.53) 0.14 (0.22) 















	   	  
	    245 (d0) 246 (d1) 247 (d2) 248 (d3) 
0.5  5 0.96 0.01 (0.25) 0.02 (0.5) 0.01 (0.25) 
1  11 0.94 0.03 (0.5) 0.02 (0.33) 0.01 (.17) 
1.5  21 0.91 0.03 (0.33) 0.05 (0.55) 0.01 (0.12) 
2.5  38 0.81 0.07 (0.37) 0.11(0.58) 0.01 (0.05) 
4 61 0.66 0.09 (0.26) 0.2 (0.59) 0.05 (0.15) 
6  79 0.41 0.14 (0.23) 0.31 (0.54) 0.14 (0.23) 
9 96 0.23 0.12 (0.15) 0.4 (0.52) 0.25 (0.32) 


































n (%)* ± 
S. D 




	   	  
	    245 (d0)  246 (d1)  247 (d2)  248 (d3)  
0.5  7 ± 2 0.93 ± 0.03  0.03 ± 0.03 
(0.42 ± 0.21) 
0.03 ± 0.01 
(0.42 ± 0.1) 
0.01 ± 0 
(0.16 ± 0.11) 
1  15 ± 4 0.92 ± 0.03 0.03 ± 0  
(0.4 ± 0.2) 
0.04 ± 0.03 
(0.45 ± 0.15) 
0.01 ± 0.01 
(0.15 ± 0.05) 
1.5  27 ± 8 0.88 ± 0.04 0.04 ± 0.01 
(0.33 ± 0.02) 
0.07 ± 0.02 
(0.55 ± 0.03) 
0.01 ± 0.01 
(0.12 ± 0.06) 
2.5  44 ± 8 0.8 ± 0.01 0.07 ± 0 
(0.36 ± 0) 
0.11 ± 0 
(0.54 ± 0.02) 
0.02 ± 0.01 
(0.1 ± 0.02) 
4 64 ± 3 0.66 ± 0.01 0.11 ± 0.01 
(0.28 ± 0.03) 
0.2 ± 0 (0.57 
± 0.02) 
0.05 ± 0 
(0.15 ± 0.01) 
6  74 ± 7 0.41 ± 0 0.14 ± 0.01 
(0.24 ± 0.01) 
0.31 ± 0 
(0.54 ± 0) 
0.14 ± 0 
(0.23 ± 0) 
9 96 ± 0 0.23 ± 0 0.12 ± 0 
(0.16 ± 0) 
0.4 ± 0 (0.52 
± 0) 
0.25 ± 0 
(0.32 ± 0) 
12.5 97 ± 5 0.39 ± 0.12 0.09 ± 0 
(0.07 ± 0) 
0.39 ± 0.07 
(0.67 ± 0.24) 
0.17 ± 0.12 
(0.27 ± 0.14) 
 
Assay conditions: 2 mM IPP, 12 mM L-Trp, 0.1 mg/mL BSA, 10 mM MgCl2, 1 µM 
IDI-1, 40 µM 4-DMATS pD 7.8, 30 oC, reaction volume 2.5 mL. 9h is not average. 
*Conversions of IPP were quantified by RP-HPLC on a phenyl column. Data in 





















	   	  
	    245 (d0) 246 (d1) 247 (d2) 248 (d3) 
1  6 0.71 0.01 (0.04) 0.27 (0.93) 0.01 (0.03) 
4  25 0.35 0.02 (0.03) 0.59 (0.9) 0.05 (0.07) 
8  51 0.11 0.02 (0.02) 0.76 (0.85) 0.11 (0.13) 
12 70 0.45 0.14 (0.24) 0.31 (0.56) 0.11 (0.19) 
24  100 0.32 0.04 (0.05) 0.59 (0.86) 0.06 (0.09) 
 











	   	  
	    245 (d0) 246 (d1) 247 (d2) 248 (d3) 
1  3 0.88 0.03 (0.24) 0.08 (0.7) 0.01 (0.05) 
4  16 0.79 0.05 (0.22) 0.15 (0.74) 0.01 (0.04) 
6  26 0.76 0.06 (0.26) 0.15 (0.62) 0.03 (0.12) 
8 36 0.66 0.09 (0.26) 0.2 (0.59) 0.05 (0.16) 
12  53 0.17 0.03 (0.03) 0.7 (0.84) 0.11 (0.13) 



















	   	  
	    245 (d0) 246 (d1) 247 (d2) 248 (d3) 
1  7 0.82 0.01 (0.05) 0.16 (0.9) 0.01 (0.05) 
4  27 0.68 0.04 (0.13) 0.26 (0.82) 0.02 (0.06) 
6  37 0.58 0.06 (0.14) 0.33 (0.78) 0.04 (0.09) 
6 42 0.67 0.06 (0.19) 0.24 (0.7) 0.04 (0.12) 
8 55 0.4 0.05 (0.09) 0.48 (0.8) 0.07 (0.11) 
12 76 0.17 0.05 (0.07) 0.64 (0.77) 0.14 (0.16) 
12 77 0.1 0.04 (0.05) 0.71 (0.77) 0.16 (0.18) 








































	   	  
	    245 (d0) ± 
S.D 
246 (d1) ± 
S.D 
247 (d2) ± 
S.D 
248 (d3) ± 
S.D 
1  5 ± 2 0.81 ± 0.09 0.02 ± 0.01 
(0.11 ± 0.11) 
0.17 ± 0.09 
(0.84 ± 12) 
0.01 ± 0 
(0.04 ± 
0.01) 
4  22 ± 6 0.74 ± 0.08 0.04 ± 0.01 
(0.17 ± 0.07) 
0. 2 ± 0.08 
(0.78 ± 
0.06) 
0.01 ± 0.01 
(0.05 ± 
0.01) 
6  35 ± 8 0.67 ± 0.09 0.06 ± 0  
(0.2 ± 0.06) 
0.24 ± 0.09 
(0.7 ± 0.08) 
0.04 ± 0.01 
(0.11 ± 
0.02) 
8  47 ± 10 0.53 ± 0.19 0.07 ± 0.02 
(0.17 ± 0.12) 
0.34 ± 0.2 
(0.75 ± 
0.14) 
0.06 ± 0.01 
(0.13 ± 
0.03) 
12 69 ± 11 0.15 ± 0.04 0.04 ± 0.01 
(0.05 ± 0.02) 
0.68 ± 0.04 
(0.79 ± 
0.04) 
0.13 ± 0.03 
(0.17 ± 
0.03) 
24  100 ± 0 0.26 ± 0.07 0.05 ± 0.01 
(0.06 ± 0.01) 
0.62 ± 0.03 
(0.83 ± 
0.04) 
0.08 ± 0.02 
(0.1 ± 0.02) 
 
Assay conditions: 2 mM IPP, 10 mM L-Trp, 0.5 mM FMN, 5 mM Na2S2O4, 0.1 mg/mL 
BSA, 10 mM MgCl2, 10 nM spIDI-2, 10 µM 4-DMATS pD 7.8, 30 oC, reaction volume 
5.2 mL. Data highlighted in red were not considered for average analysis. *Conversions 
of IPP were quantified by RP-HPLC on a phenyl column. Data in parentheses indicates 



























7 ± 2 0.48	   0.52 
15 ± 4 0.43 0.57 
27 ± 8 0.38 0.62 
44 ± 8 0.40 0.60 
64 ± 3 0.33 0.67 
74 ± 7 0.31 0.69 
96 ± 0 0.23 0.77 




5 ± 2 0.12 0.88 
22 ± 6 0.18 0.82 
35 ± 8 0.22 0.78 
47 ± 10 0.19 0.81 
69 ± 11 0.06 0.94 
100 ± 0 0.07 0.93 






















Scheme 4.3. Deuterium incorporation and partitioning of substrates and products in A) 















































E . E . E .
E .E .

















































































E . E .
d1-DMAPP
E . E .
E . E .E .E .E .






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Exact mass = 295.1417 [M+Na]+
Molecular formula = C16H20N2O2 Molecular formula = C16H19DN2O2



















Exact mass = 297.1543 [M+Na]+
Molecular formula = C16H18D2N2O2 Molecular formula =  C16H17D3N2O2
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Exact mass = 244.9985 [M-H]-
Molecular formula = C5H12O7P2 Molecular formula = C5H11DO7P2
Molecular formula = C5H11DO7P2 Molecular formula = C5H11DO7P2
Exact mass = 246.0048 [M-H]-
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